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Background: Venous thromboembolism (VTE) is a common source of perioperative morbidity and
mortality.
Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend
to support decision making about preventing VTE in patients undergoing surgery.
Methods: ASH formed a multidisciplinary guideline panel balanced to minimize bias from conflicts
of interest. The McMaster University GRADE Centre supported the guideline-development process,
including performing systematic reviews. The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which
were subject to public comment.
Results: The panel agreed on 30 recommendations, including for major surgery in general (n 5 8),
orthopedic surgery (n 5 7), major general surgery (n 5 3), major neurosurgical procedures (n 5 2),
urological surgery (n5 4), cardiac surgery and major vascular surgery (n5 2), major trauma (n5 2), and
major gynecological surgery (n 5 2).
Conclusions: For patients undergoing major surgery in general, the panel made conditional recommen-
dations for mechanical prophylaxis over no prophylaxis, for pneumatic compression prophylaxis over
graduated compression stockings, and against inferior vena cava filters. In patients undergoing total hip or
total knee arthroplasty, conditional recommendations included using either aspirin or anticoagulants, as well
as for a direct oral anticoagulant over low-molecular-weight heparin (LMWH). For major general surgery, the
panel suggested pharmacological prophylaxis over no prophylaxis, using LMWH or unfractionated heparin.
For major neurosurgery, transurethral resection of the prostate, or radical prostatectomy, the panel
suggested against pharmacological prophylaxis. For major trauma surgery or major gynecological surgery,
the panel suggested pharmacological prophylaxis over no prophylaxis.
Summary of recommendations
These American Society of Hematology (ASH) guidelines are based on updated and original systematic
reviews of evidence conducted by researchers and developed under the direction of the McMaster
Submitted 13 September 2019; accepted 22 October 2019. DOI 10.1182/
bloodadvances.2019000975.
The full-text version of this article contains a data supplement.
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University GRADE Centre with international collaborators. The
panel followed best practice for guideline development recom-
mended by the Institute of Medicine (now the National Academy of
Medicine) and the Guidelines International Network.1-4 The panel
used the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach5,6 to assess the certainty in the
evidence and formulate recommendations.
The population of postoperative patients is heterogeneous with
regard to the degree of risk of venous thromboembolism (VTE),
depending on intrinsic patient factors and those factors that are
related to the type of surgery, mobilization, anatomic location of the
procedures, and risk of bleeding. Surgeons have a long history of
accepting prophylactic measures against VTE, be they mechanical
or pharmacological.
Interpretation of strong and
conditional recommendations
The strength of a recommendation is expressed as strong (“the
guideline panel recommends…”) or conditional (“the guideline
panel suggests…”) and has the following interpretation:
Strong recommendation
c For patients: most individuals in this situation would want the
recommended course of action, and only a small proportion
would not.
c For clinicians: most individuals should follow the recommended
course of action. Formal decision aids are not likely to be needed
to help individual patients make decisions consistent with their
values and preferences.
c For policy makers: the recommendation can be adopted as
policy in most situations. Adherence to this recommendation
according to the guideline could be used as a quality criterion or
performance indicator.
c For researchers: the recommendation is supported by credible
research or other convincing judgments that make additional
research unlikely to alter the recommendation. On occasion, a
strong recommendation is based on low or very low certainty in
the evidence. In such instances, further research may provide
important information that alters the recommendation.
Conditional recommendation
c For patients: the majority of individuals in this situation would
want the suggested course of action, but many would not. De-
cision aids may be useful in helping patients to make decisions
consistent with their individual risks, values, and preferences.
c For clinicians: different choices will be appropriate for individ-
ual patients, and clinicians must help each patient to arrive at a
management decision consistent with the patient’s values and
preferences. Decision aids may be useful in helping individuals
to make decisions consistent with their individual risks, values,
and preferences.
c For policy makers: policy-making will require substantial debate
and involvement of various stakeholders. Performance mea-
sures about the suggested course of action should focus
on whether an appropriate decision-making process is duly
documented.
c For researchers: this recommendation is likely to be strength-
ened (for future updates or adaptation) by additional research.
An evaluation of the conditions and criteria (and the related
judgments, research evidence, and additional considerations)
that determined the conditional (rather than strong) recommen-
dation will help to identify possible research gaps.
Recommendations
Mechanical vs pharmacological prophylaxis for patients
undergoing major surgery
RECOMMENDATIONS 1 TO 5. For patients undergoing major surgery,
the ASH guideline panel suggests the following:
1. Using pharmacological prophylaxis or mechanical prophylaxis
(conditional recommendation based on low certainty in the
evidence of effects ÅÅ◯◯)
2. For patients who do not receive pharmacologic prophylaxis,
using mechanical prophylaxis over no mechanical prophylaxis
(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯).
3. For patients who receive mechanical prophylaxis, using inter-
mittent compression devices over graduated compression
stockings (conditional recommendation based on very low
certainty in the evidence of effects Å◯◯◯).
4. For patients who receive pharmacologic prophylaxis, using
combined prophylaxis with mechanical and pharmacological
methods over prophylaxis with pharmacological agents alone
(conditional recommendation based on very low certainty in
the evidence of effects Å◯◯◯).
5. Depending on the risk of VTE and bleeding based on the
individual patient and the type of surgical procedure, using
combined prophylaxis or mechanical prophylaxis alone
(conditional recommendation based on low certainty in the
evidence of effects ÅÅ◯◯).
Remarks: For patients considered at high risk of bleeding, the
balance of effects may favor mechanical methods over pharmaco-
logical prophylaxis. For patients considered at high risk for VTE,
combined prophylaxis is particularly favored over mechanical or
pharmacological prophylaxis alone.
Prophylactic insertion of an inferior vena cava filter
RECOMMENDATION 6. For patients undergoing major surgery, the
ASH guideline panel suggests against using inferior vena cava
(IVC) filters for prophylaxis of VTE (conditional recommendation
based on very low certainty in the evidence of effects, Å◯◯◯).
Timing of antithrombotic prophylaxis
RECOMMENDATIONS 7 AND 8. For patients undergoing major
surgery, the ASH guideline panel suggests using extended
antithrombotic prophylaxis over short-term antithrombotic pro-
phylaxis (conditional recommendation based on very low certainty in
the evidence of effects Å◯◯◯). The ASH guideline panel further
suggests using early or delayed antithrombotic prophylaxis (condi-
tional recommendation based on very low certainty in the evidence
of effects Å◯◯◯). Remarks: Extended prophylaxis was generally
considered as beyond 3 weeks (range, 19-42 days) compared with
short-term prophylaxis, which was considered as up to 2 weeks
(range, 4-14 days). Twelve hours following surgery was arbitrarily
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selected to be the cutoff point between early and late postoperative
antithrombotic administration.
Orthopedic surgery
RECOMMENDATIONS 9 TO 13. For patients undergoing total hip
arthroplasty or total knee arthroplasty, the ASH guideline panel
suggests using aspirin (ASA) or anticoagulants (conditional
recommendation based on very low certainty in the evidence of
effects Å◯◯◯). When anticoagulants are used, the panel suggests
using direct oral anticoagulants (DOACs) over low-molecular-
weight heparin (LMWH) (conditional recommendation based on
moderate certainty in the evidence of effects ÅÅÅ◯); the panel
suggests using any of the DOACs approved for use (condi-
tional recommendation based on low certainty in the evidence of
effects ÅÅ◯◯). If a DOAC is not used, the panel suggests using
LMWH rather than warfarin (conditional recommendation based
on very low certainty in the evidence of effects Å◯◯◯) and
recommends LMWH rather than unfractionated heparin (UFH)
(strong recommendation based on moderate certainty in the evidence
of effects ÅÅÅ◯).
RECOMMENDATIONS 14 AND 15. For patients undergoing hip fracture
repair, the ASH guideline panel suggests using pharmacological
prophylaxis over no pharmacological prophylaxis (conditional
recommendation based on very low certainty in the evidence of
effects Å◯◯◯) and suggests using LMWH or UFH (conditional
recommendation based on very low certainty in the evidence of
effects Å◯◯◯).
Major general surgery
RECOMMENDATIONS16AND17. For patients undergoing major general
surgery, the ASH guideline panel suggests using pharmacologi-
cal prophylaxis over no pharmacological prophylaxis (conditional
recommendation based on low certainty in the evidence of effects
ÅÅ◯◯) and suggests using LMWH or UFH (conditional recom-
mendation based on very low certainty in the evidence of effects
Å◯◯◯).
Laparoscopic cholecystectomy
RECOMMENDATION 18. For patients undergoing laparoscopic chole-
cystectomy, the ASH guideline panel suggests against using
pharmacological prophylaxis (conditional recommendation based
on very low certainty in the evidence of effects Å◯◯◯). Remark:
Patients with other risk factors for VTE (such as history of VTE,
thrombophilia, or malignancy) may benefit from pharmacological
prophylaxis.
Major neurosurgical procedures
RECOMMENDATIONS 19 AND 20. For patients undergoing major
neurosurgical procedures, the ASH guideline panel suggests
against using pharmacological prophylaxis (conditional recom-
mendation based on very low certainty in the evidence of effects
Å◯◯◯). For the subset of patients undergoing major neurosur-
gical procedures for whom pharmacological prophylaxis is used,
the ASH guideline panel suggests using LMWH over UFH (condi-
tional recommendation based on very low certainty in the evidence of
effects Å◯◯◯). Remarks: Patients undergoing major neurosurgical
procedures are expected to receive prophylaxis with mechanical
methods. Pharmacological prophylaxis may be warranted in a higher-
risk subgroup of patients, such as those experiencing prolonged
immobility following surgery. In addition, pharmacological prophylaxis
could be considered for patients undergoing major neurosurgical
procedures that carried a lower risk for major bleeding and in those
patients with persistent mobility restrictions after the bleeding risk
declines following surgery.
Urological procedures
RECOMMENDATIONS 21 AND 22. For patients undergoing transurethral
resection of the prostate (TURP), the ASH guideline panel suggests
against using pharmacological prophylaxis (conditional recommen-
dation based on very low certainty in the evidence of effects
Å◯◯◯). For the subset of patients undergoing TURP for whom
pharmacological prophylaxis is used, the ASH guideline panel
suggests using LMWH or UFH (conditional recommendation
based on very low certainty in the evidence of effects Å◯◯◯).
Remark: Patients with other risk factors for VTE (such as history
of VTE, thrombophilia, or malignancy) may benefit from pharma-
cological prophylaxis.
RECOMMENDATIONS 23 AND 24. For patients undergoing radical
prostatectomy, the ASH guideline panel suggests against using
pharmacological prophylaxis (conditional recommendation based
on very low certainty in the evidence of effects Å◯◯◯). For patients
undergoing radical prostatectomy in whom pharmacological pro-
phylaxis is used, the ASH guideline panel suggests using LMWH
or UFH (conditional recommendation based on very low certainty
in the evidence of effects Å◯◯◯). Remark: Patients undergoing
an extended node dissection and/or open radical prostatectomy
may have a higher VTE risk and may potentially benefit from
pharmacological prophylaxis.
Cardiac or major vascular surgery
RECOMMENDATIONS 25 AND 26. For patients undergoing cardiac or
major vascular surgery, the ASH guideline panel suggests using
pharmacological prophylaxis or no pharmacological prophylaxis (condi-
tional recommendation based on very low certainty in the evidence of
effects Å◯◯◯). When pharmacological prophylaxis is used, the panel
suggests using LMWH or UFH (conditional recommendation based on
very low certainty in the evidence of effects Å◯◯◯).
Major trauma
RECOMMENDATION 27A. For patients experiencing major trauma and
who are at low to moderate risk for bleeding, the ASH guideline
panel suggests using pharmacological prophylaxis over no pharma-
cological prophylaxis (conditional recommendation based on very low
certainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 27B. For patients experiencing major trauma and
who are at high risk for bleeding, the ASH guideline panel
suggests against pharmacological prophylaxis (conditional recom-
mendation based on very low certainty in the evidence of effects
Å◯◯◯).
RECOMMENDATION 28. For patients experiencing major trauma in
whom pharmacological prophylaxis is used, the ASH guideline
panel suggests using LMWH or UFH (conditional recommendation
based on low certainty in the evidence of effects ÅÅ◯◯).
Major gynecological surgery
RECOMMENDATIONS 29 AND 30. For patients undergoing major
gynecological surgery, the ASH guideline panel suggests using
pharmacological prophylaxis over no pharmacological prophylaxis
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(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯) and suggests using LMWH or UFH
(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯).
Introduction
Aim of these guidelines and specific objectives
The purpose of these guidelines is to provide evidence-based
recommendations about the prevention of VTE for patients un-
dergoing major surgical procedures. The target audience includes
patients, surgeons, intensivists, internists, hematologists, general
practitioners, hospitalists, other clinicians, pharmacists, and deci-
sion makers. Policy makers interested in these guidelines include
those involved in developing local, national, or international programs
aiming to safely reduce the incidence of VTE and/or to evaluate direct
and indirect harms and costs related to VTE and its prevention. This
document may also serve as the basis for adaptation by local,
regional, or national guideline panels.
Description of the health problem
Deep vein thrombosis (DVT) and pulmonary embolism (PE) (collectively,
VTE) are well-recognized, clinically important, and potentially
devastating complications that may occur following major surgical
procedures, defined as any surgical intervention that carries greater
than minimal risk, is performed in the operating room, and requires
specialized training. Before the era of the routine use of effective
prophylaxis, VTE was a common cause of morbidity and mortality
following major surgery. It has been estimated to cause .50 000
deaths per annum in the United States alone.7 The importance of
preventative measures to minimize the risk of VTE following major
surgery has been recognized for decades; however, even with the
use of prophylaxis, surgery accounts for;25% of VTEs observed in
communities.8
Although most surgical procedures carry some risk for VTE, this risk
varies considerably across surgical procures and among individu-
al patients undergoing surgery. Surgical procedures carrying the
highest risk of developing postoperative VTE include hip and knee
arthroplasty, invasive neurosurgical procures, and major vascular
procedures.9
Patient factors that carry greater risks for thrombosis include
histories of VTE, particularly if unprovoked or associated with
cancer, or cancer, even in the absence of previous VTE. Scoring
systems that calculate the risk of postoperative VTE for individual
patients, such as the Caprini score, have been developed and
validated following some surgical procedures.10
Although postoperative VTE has historically been a complication
primarily occurring in the hospital, with shortened hospital stays,
postoperative VTE often occurs in the days to weeks following
discharge from the hospital.11
Description of the target populations
The primary target population of this guideline is patients hospitalized
for major surgical procedures that carry a risk for postoperative VTE.
This guideline also addresses patients hospitalized following
major trauma; most, but not all, subsequently required major
surgical procedures. The panel recognized that there are 2 major
modalities applied for the prevention of VTE in the postoperative
period: pharmacological antithrombotic prophylaxis and mechanical
prophylaxis. For evaluation of the pharmacological methods for
the prevention of VTE, the panel weighed the benefits and risks
of the various options for individual surgical procedures or
domains, such as hip or knee arthroplasty, general surgery, or
urological or neurosurgical procedures.
For mechanical interventions, such as graduated or mechanical
compression devices or IVC filters, the effectiveness of these
interventions was assessed across all surgical domains. Likewise,
other questions, such as the duration of pharmacological pro-
phylaxis and timing of the initiation of pharmacological prophylaxis,
were also assessed across all surgical domains.
The target populations included patients who underwent surgery for
cancer or noncancer-related procedures. Patients hospitalized for
major trauma were included whether they underwent surgery or not.
Methods
The guideline panel developed and graded the recommendations
and assessed the certainty in the supporting evidence following the
GRADE approach.5,6,12-16 The overall guideline-development pro-
cess, including funding of the work, panel formation, management
of conflicts of interest, internal and external review, and organiza-
tional approval, was guided by ASH policies and procedures
derived from the Guidelines International Network–McMaster
Guideline Development Checklist (http://cebgrade.mcmaster.ca/
guidecheck.html) and was intended to meet recommendations
for trustworthy guidelines by the Institute of Medicine and the
Guidelines International Network.1-4
Organization, panel composition, planning,
and coordination
The work of this panel was coordinated with 9 other guideline
panels (addressing other aspects of VTE management) by ASH
and the McMaster GRADE Centre (funded by ASH under a paid
agreement). Project oversight was provided initially by a coordina-
tion panel, which reported to the ASH Committee on Quality, and
then by the coordination panel chair (Adam Cuker) and vice chair
(H.J.S.). ASH vetted and appointed individuals to the guideline
panel. The McMaster GRADE Centre vetted and retained re-
searchers to conduct systematic reviews of evidence and coordi-
nate the guideline-development process, including the use of the
GRADE approach. The membership of the panels and the GRADE
Centre team is described in Supplement 1.
The panel included surgeons with subspecialty representa-
tion, hematologists, internists, and a pharmacist, all of whom had
clinical and research expertise on the guideline topic. The panel
also included methodologists with expertise in evidence appraisal
and guideline development and 2 patient representatives. Both
patient representatives participated in question prioritization,
and 1 participated in all remaining steps of the development
process. The panel chair was a content expert. The vice chair
was a urological surgeon with specialized expertise in guideline
development.
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In addition to synthesizing evidence systematically, the McMaster
GRADE Centre supported the guideline-development process,
including determining methods, preparing agendas and meeting
materials, and facilitating panel discussions. The panel’s work
was done using Web-based tools (www.surveymonkey.com and
www.gradepro.org) and face-to-face and online meetings.
Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by ASH, a
nonprofit medical specialty society that represents hematologists.
Some members of the guideline panel were members of ASH. ASH
staff supported panel appointments and coordinated meetings but
had no role in choosing the guideline questions or determining the
recommendations.
Members of the guideline panel received travel reimbursement for
attendance at in-person meetings. The patient representative (C.B.)
received an honorarium of $200. The panelists received no other
payments. Some researchers who contributed to the system-
atic evidence reviews received salary or grant support through
the McMaster GRADE Centre. Other researchers participated
to fulfill requirements of an academic degree or program.
Conflicts of interest of all participants were managed according
to ASH policies based on recommendations of the Institute of
Medicine17 and the Guidelines International Network.4 At the time
of appointment, a majority of the guideline panel, including the chair
and the vice chair, had no conflicts of interest as defined and judged
by ASH (ie, no current material interest in any commercial entity with a
product that could be affected by the guidelines). Some panelists
disclosed new interests or relationships during the development
process, but the majority continued to have no conflicts of interest
with commercial entities, as judged by ASH.
Before appointment to the panel, individuals disclosed financial and
nonfinancial interests. Members of the VTE Guideline Coordination
Panel reviewed the disclosures and judged which interests were
conflicts and should be managed. Supplement 2 provides the
complete “Disclosure of Interests” forms of all panel members.
In Part A of the forms, individuals disclosed material interests
for 2 years prior to appointment. In Part B, they disclosed other
interests that were not mainly financial. Part C summarizes ASH
decisions about which interests were judged to be conflicts.
Part D describes new interests disclosed by individuals after
appointment.
Recusal was used to manage conflicts of interest. During
deliberations, panel members with a current direct financial
interest in a commercial entity with any product that could be
affected by the guidelines participated in discussions about the
evidence and clinical context but were recused from making
judgments or voting about individual domains (eg, magnitude of
desirable consequences) and the direction and strength of
relevant recommendations.4,18-20 The Evidence-to-Decision
(EtD) framework for each recommendation describes which
individuals were recused from making judgments about each
recommendation.
None of the McMaster-affiliated researchers who contributed to
the systematic evidence reviews or who supported the guideline-
development process had any current material interest in a com-
mercial entity with any product that could be affected by the
guidelines. Supplement 3 provides the complete “Disclosure of
Interest” forms of researchers who contributed to these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
The panel used the GRADEpro Guideline Development Tool
(www.gradepro.org) and SurveyMonkey (www.surveymonkey.com)
to brainstorm and then prioritize the questions described in Table 1.
The panel selected outcomes of interest for each question a priori,
following an approach described in detail elsewhere.21 The panel
rated the following outcomes as critical for clinical decision making
across all questions: mortality, symptomatic PEs, symptomatic
proximal DVTs, symptomatic severe distal DVTs, major bleeding,
and reoperation. The panel used an explicit process to rate the
clinical severity of DVTs and PEs. The panel determined that all
symptomatic proximal DVTs and PEs confirmed by objective
diagnostic imaging were considered of moderate severity and
were clinically important.22 For several outcomes, the studies
reported outcomes that were different or were in addition to the
outcomes that the panel determined to be important for decision
making. Typically, included studies reported outcomes as any
PE, any DVT, or any proximal or distal DVT. Some studies did not
distinguish asymptomatic thromboembolic events that were detected
by the routine performance of sensitive screening studies for VTEs
from symptomatic thromboembolic events where patients devel-
oped overt symptoms that were subsequently confirmed by objective
testing to be associated with VTEs. Reporting of symptomatic
thromboembolic events was inconsistent across studies.
Where available, questions were addressed with studies that
reported symptomatic outcome events. In the absence of reports of
symptomatic VTE in a clinical question, modeling was performed
using estimates of the proportion of asymptomatic DVTs that would
become clinically important symptomatic events (Supplement 4).
Only “severe” distal DVTs were rated as clinically important distal
DVTs, and it was estimated that only ;25% of symptomatic
postoperative distal DVTs would be considered severe.
Major bleeding definitions varied across clinical studies. For the
purposes of this analysis, outcome events that met the definition of
major bleeding for individual studies were applied. The exception
was that the need for a blood transfusion itself was not considered
major bleeding unless other criteria for major bleeding were met.
The definition of reoperation was not specific for reoperation
caused by or related to major bleeding.
Studies evaluated included patients with cancer and without cancer.
We tested potential differences in the effects on studies with.50%
and ,50% of participants with cancer. Subgroup analyses did not
demonstrate a difference in the relative effectiveness of interventions
whether cancer patients were included or not. As a result, recom-
mendations do not distinguish between cancer and noncancer patients.
For the use of pharmacological and mechanical methods of
prophylaxis, the panel advises to follow manufacturer’s recommen-
dations regarding patient-specific restrictions in the use of individ-
ual products (such as levels of renal function for patients receiving
LMWHs or DOACs). The panel also advises periodic monitoring of
the platelet count for patients receiving LMWH and, in particular,
UFH, as postoperative prophylaxis in consideration of the risk of
heparin-induced thrombocytopenia.
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Evidence review and development
of recommendations
For each guideline question, the McMaster GRADECentre prepared a
GRADE EtD framework, using the GRADEpro Guideline Development
Tool (www.gradepro.org).12,13,16 The EtD table summarized the results
of systematic reviews of the literature that were updated or performed
for this guideline. The EtD table addressed effects of interven-
tions, resource utilization (cost-effectiveness), values and prefer-
ences (relative importance of outcomes), equity, acceptability, and
feasibility. The guideline panel reviewed draft EtD tables before,
during, or after the guideline panel meeting and made suggestions
for corrections and identified missing evidence. To ensure that recent
studies were not missed, searches (Supplement 5) were updated
during October and November 2016, and panel members were asked
to suggest any studies that may have been considered missed and
fulfilled the inclusion criteria for the individual questions. Monthly search
alerts were created and monitored to capture relevant new studies up
to 1 July 2019, prior to submission of the manuscript for publication.
Under the direction of the McMaster GRADE Centre, researchers
followed the general methods outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (handbook.cochrane.org)
for conducting updated or new systematic reviews of intervention
effects. When existing reviews were used, judgments of the original
authors about risk of bias were randomly checked for accuracy
and accepted or conducted de novo if they were not available or
not reproducible. For new reviews, risk of bias was assessed at
the health outcome level using the Cochrane Collaboration’s risk
of bias tool for randomized trials or nonrandomized studies. In
addition to conducting systematic reviews of intervention effects,
the researchers searched for evidence related to baseline risks,
values, preferences, and costs and summarized findings within
the EtD frameworks.12,13,16 Subsequently, the certainty in the
body of evidence (also known as quality of the evidence or confidence
in the estimated effects) was assessed for each effect estimate of the
outcomes of interest following the GRADE approach based on the
following domains: risk of bias, precision, consistency and magnitude
of the estimates of effects, directness of the evidence, risk of publication
bias, presence of large effects, dose-response relationship, and an
assessment of the effect of residual, opposing confounding. The
certainty was categorized into 4 levels ranging from very low to high.5,6,14
During a 2-day in-person meeting, followed by online communication
and conference calls, the panel developed clinical recommendations
based on the evidence summarized in the EtD tables. For each recom-
mendation, the panel took a population perspective and came to
consensus on the following: the certainty in the evidence, the balance
of benefits and harms of the compared management options, and the
assumptions about the values and preferences associated with the
decision. The guideline panel also explicitly took into account the extent
of resource use associated with alternative management options. The
panel agreed on the recommendations (including direction and
strength), remarks, and qualifications by consensus or, in rare instances,
by voting (an 80%majority was required for a strong recommendation),
based on the balance of all desirable and undesirable consequences. In
the event that consensus was not reached based on discussion, the
recommendation was made based on a vote of the panel, with the
results of such votes listed in the text following the recommendation.
The final guidelines, including recommendations, were reviewed and
approved by all members of the panel.
Interpretation of strong and
conditional recommendations
The recommendations are labeled as “strong” or “conditional”
according to the GRADE approach. The words “the guideline panel
recommends” are used for strong recommendations, and “the
guideline panel suggests” is used for conditional recommendations.
Table 1. Prioritized clinical questions
Perioperative VTE prophylaxis in major surgery in general
1. Pharmacological prophylaxis vs mechanical prophylaxis
2. Mechanical prophylaxis vs no prophylaxis
3. Pneumatic compression devices vs graduated compression stockings
4. Pharmacological prophylaxis combined with mechanical prophylaxis vs
pharmacological prophylaxis alone
5. Mechanical prophylaxis combined with pharmacological prophylaxis vs mechanical
prophylaxis alone
6. Insertion of an IVC filter vs no IVC filter
7. Extended antithrombotic prophylaxis vs short-term antithrombotic prophylaxis
8. Early vs delayed antithrombotic prophylaxis
Orthopedic surgery: total hip and knee arthroplasty
9. ASA prophylaxis vs anticoagulants
10. DOAC prophylaxis vs LMWH prophylaxis
11. DOAC prophylaxis vs prophylaxis with another DOAC
12. LMWH prophylaxis vs warfarin prophylaxis
13. LMWH prophylaxis vs UFH prophylaxis
Orthopedic surgery: hip fracture repair
14. Pharmacological prophylaxis vs no pharmacological prophylaxis
15. LMWH prophylaxis vs UFH prophylaxis
Major general surgery
16. Pharmacological prophylaxis vs no pharmacological prophylaxis
17. LMWH prophylaxis vs UFH prophylaxis
Laparoscopic cholecystectomy
18. Pharmacological prophylaxis vs no pharmacological prophylaxis
Major neurosurgical procedures
19. Pharmacological prophylaxis vs no pharmacological prophylaxis
20. LMWH prophylaxis vs UFH prophylaxis
TURP
21. Pharmacological prophylaxis vs no pharmacological prophylaxis
22. LMWH prophylaxis vs UFH prophylaxis
Radical prostatectomy
23. Pharmacological prophylaxis vs no pharmacological prophylaxis
24. LMWH prophylaxis vs UFH prophylaxis
Cardiac or major vascular surgery
25. Pharmacological prophylaxis vs no pharmacological prophylaxis
26. LMWH prophylaxis vs UFH prophylaxis
Major trauma
27. Pharmacological prophylaxis vs no pharmacological prophylaxis
28. LMWH prophylaxis vs UFH prophylaxis
Major gynecological surgery
29. Pharmacological prophylaxis vs no pharmacological prophylaxis
30. LMWH prophylaxis vs UFH prophylaxis
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Table 2 provides the suggested interpretation of strong and
conditional recommendations by patients, clinicians, and health
care policy makers.
Document review
Draft recommendations were reviewed by all members of the panel,
revised, and then made available online on 22 June 2018 for
external review by stakeholders, including allied organizations,
other medical professionals, patients, and the public. Sixteen individuals
or organizations submitted comments. The document was revised
to address pertinent comments, but no changes were made to the
recommendations. The guidelines were reviewed by the ASH
Guideline Oversight Subcommittee on 28 August 2019, approved
by the Committee on Quality on 6 September 2019 and by the ASH
officers on 13 September 2019, and then subjected to peer review.
How to use these guidelines
ASH guidelines are primarily intended to help clinicians make
decisions about diagnostic and treatment alternatives. Other
purposes are to inform policy, education, and advocacy and to
state future research needs. They may also be used by patients.
These guidelines are not intended to serve or be construed as a
standard of care. Clinicians must make decisions on the basis
of the clinical presentation of each individual patient, ideally
through a shared process that considers the patient’s values
and preferences with respect to the anticipated outcomes of
the chosen option. Decisions may be constrained by the realities of a
specific clinical setting and local resources, including, but not limited to,
institutional policies, time limitations, and availability of treatments. These
guidelines may not include all appropriate methods of care for the
clinical scenarios described. As science advances and new evidence
becomes available, recommendationsmay become outdated. Following
these guidelines cannot guarantee successful outcomes. ASH does
not warrant or guarantee any products described in these guidelines.
Statements about the underlying values and preferences, as well
as qualifying remarks accompanying each recommendation, are its
integral parts and serve to facilitate more accurate interpretation.
They should never be omitted when recommendations from these
guidelines are quoted or translated. Implementation of the guidelines
will be facilitated by the related interactive forthcoming decision aids.
The use of these guidelines is also facilitated by the links to the EtD
frameworks and interactive summary-of-findings tables in each section.
Recommendations
Mechanical vs pharmacological prophylaxis for
patients undergoing major surgery
Question: Should pharmacological prophylaxis vs mechanical
prophylaxis be used for patients undergoing major surgery?
Recommendation 1
For patients undergoing major surgery, the ASH guideline panel
suggests using pharmacological prophylaxis or mechanical
prophylaxis (conditional recommendation based on low certainty
in the evidence of effects ÅÅ◯◯). Remark: For patients
considered at high risk for bleeding, the balance of effects may
favor mechanical methods over pharmacological prophylaxis.
Summary of the evidence. We identified 11 systematic
reviews addressing, in part, this question.23-33 We identified
38 studies in this review that fulfilled our inclusion criteria and
measured outcomes relevant to this context.34-72 Our system-
atic search of randomized controlled trials (RCTs) identified 2
additional studies not included in previous systematic reviews
and that fulfilled the inclusion criteria.70,72
Fifteen studies reported the effect of the pharmacological pro-
phylaxis compared with mechanical prophylaxis alone on risk of
mortality.35,36,40,42,51,54,57,59-61,63-65,68,72 Thirteen studies reported
the effect on the development of symptomatic PEs,35,37,39,43,45,62,64,67-72
and 17 studies reported the effect on the development on any
PE.34,36,38,40,42,46,47,50,51,53,58,60,61,63,67,71,72 Six studies reported
data on symptomatic DVTs,35,67,69-72 and 17 studies reported data
on any proximal DVT.34,35,37,39,41,45,52,53,57,58,64,65,67,69-72 Four studies
reported data on symptomatic distal DVTs,35,70-72 and 16 studies
reported data on any distal DVT.34,35,37,39,40,45,52,53,57,58,63,64,66,67,71,72
Table 2. Interpretation of strong and conditional recommendations
Implications for: Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not.
The majority of individuals in this situation would want the
suggested course of action, but many would not. Decision aids
may be useful in helping patients to make decisions consistent
with their individual risks, values, and preferences.
Clinicians Most individuals should follow the recommended course of action.
Formal decision aids are not likely to be needed to help individual
patients make decisions consistent with their values and
preferences.
Different choices will be appropriate for individual patients;
clinicians must help each patient arrive at a management
decision consistent with the patient’s values and preferences.
Decision aids may be useful in helping individuals to make
decisions consistent with their individual risks, values, and
preferences.
Policy makers The recommendation can be adopted as policy in most situations.
Adherence to this recommendation according to the guideline
could be used as a quality criterion or performance indicator.
Policy making will require substantial debate and involvement of
various stakeholders. Performance measures should assess
whether decision making is appropriate.
Researchers The recommendation is supported by credible research or other
convincing judgments that make additional research unlikely to
alter the recommendation. On occasion, a strong
recommendation is based on low or very low certainty in the
evidence. In such instances, further research may provide
important information that alters the recommendations.
The recommendation is likely to be strengthened (for future
updates or adaptation) by additional research. An evaluation of
the conditions and criteria (and the related judgments, research
evidence, and additional considerations) that determined the
conditional (rather than strong) recommendation will help to
identify possible research gaps.
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Eighteen studies reported the effect of pharmacological prophylaxis
compared with mechanical prophylaxis alone on the risk of major
bleeding,35-37,41,42,43,48,51,54,59-61,63-66,68,72 and 6 studies reported
the effect on the risk of reoperation.37,42,46,48,54,72
The EtD framework is available at https://guidelines.gradepro.org/
profile/B57A59FE-FCA9-8C9A-8C8D-55089B4E8FB1.
Benefits. The systematic review found that there may be no
difference in mortality between pharmacological and mechanical
prophylaxis (relative risk [RR], 0.92; 95% confidence interval [CI],
0.46-1.84; low certainty in the evidence of effects); this corresponds
to 1 fewer (5 fewer to 7 more) death per 1000 patients. Similarly,
irrespective of the baseline risk chosen, which was derived from a
cohort study of 172 320 patients,73 there may be no difference for
symptomatic PEs (RR, 1.04; 95% CI, 0.36-2.96; low certainty in the
evidence of effects), corresponding to 0 fewer events (2 fewer to
7 more). There is also likely little to no difference in symptomatic
proximal DVTs (RR, 0.75; 95% CI, 0.11-5.32; moderate certainty in
the evidence of effects); depending on the baseline risk of 1.6% or
2.6%,73 this corresponds to anywhere from 4 fewer (15 fewer to
71 more) to 7 fewer (23 fewer to 113 more) events, respectively.
For symptomatic distal DVTs, pharmacological prophylaxis likely
results in a reduction in risk (RR, 0.16; 95% CI, 0.05-0.58; moderate
certainty in the evidence of effects); however, this corresponds to a
possibly small, and likely unimportant, reduction in symptomatic distal
DVTs in absolute terms of 2 fewer (1-2 fewer) per 1000 patients,
based on a baseline risk of 1.2% from observational data.73
Harms and burden. Pharmacological prophylaxis likely leads
to more major bleeding (RR, 2.87; 95% CI, 1.68-4.92; moderate
certainty in the evidence of effects). This corresponds to a small
absolute increase of 12 more (4-25 more) major bleeds per 1000
patients. Pharmacological prophylaxis probably results in no
difference in reoperations (RR, 2.01; 95% CI, 0.29-14.05; low
certainty in the evidence of effects), corresponding to 1 more (1 fewer
to 19 more) per 1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
twice for very serious imprecision.
Other EtD criteria and considerations. The panel deter-
mined that, on balance, neither approach was favored over the
other for patients undergoing major surgery at low or moderate
risk for major bleeding because of the low certainty in the
evidence, as well as concerns about compliance with mechan-
ical prophylaxis. For patients at high baseline risk for major
bleeding, mechanical prophylaxis would more clearly be favored
because of the incremental risk of bleeding with pharmacolog-
ical prophylaxis. There was possibly important uncertainty or
variability in how much affected individuals valued the main
outcomes. The panel further judged the costs associated with
pharmacological prophylaxis to be moderate based on very low
certainty in the evidence about resource requirements. Cost-
effectiveness probably favors mechanical prophylaxis. The panel
did not account for potential risks of mechanical prophylaxis,
including fall risk, risk of skin damage, and limitation in mobility.
There would probably be no impact on health equity, and
pharmacological and mechanical prophylaxis would be ac-
ceptable to stakeholders and probably feasible to implement.
The panel recognized that most of the evidence informing this
recommendation came from the orthopedic literature (elective knee
and hip arthroplasty).
Conclusions and research needs for this recommendation.
The guideline panel suggests using pharmacological prophy-
laxis or mechanical prophylaxis for patients undergoing major
surgery, based on low certainty in the evidence of effects. For
patients deemed at high risk for major bleeding (because of the
nature of the surgical procedure), there is likely a net benefit in
favor of mechanical prophylaxis.
The panel determined that it would be valuable to have further high-
quality studies comparing these interventions outside of the
orthopedic setting to confirm the generalizability of the results
across surgical domains. The panel would also welcome high-
quality studies to determine the effectiveness of mechanical
prophylaxis administered outside the hospital setting. The panel
identified the need for more and better studies on how patients
value the various outcomes in the perioperative setting and to what
degrees these values vary by patients as a future research priority.
Question: Should mechanical prophylaxis vs no prophylaxis be
used for patients undergoing major surgery?
Recommendation 2
For patients undergoing major surgery who do not receive
pharmacologic prophylaxis, the ASH guideline panel suggests
using mechanical prophylaxis over no mechanical prophylaxis
(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯).
Summary of the evidence. We identified 5 systematic
reviews addressing, in part, this question.24,25,27,28,30 We
identified 25 studies in these reviews that fulfilled our inclu-
sion criteria and measured outcomes relevant to this
context.37,49,53,66,74-94 Our systematic search of RCTs did not
identify any additional study that fulfilled the inclusion criteria.
Ten studies reported the effect of mechanical prophylaxis compared
with no prophylaxis on risk of mortality.49,77,78,81,83-85,88,90,94 Nine
studies reported the effect on the development of symptomatic
PEs,37,76,78,81,83,84,86,88,92 and 5 studies reported the effect on any
PE.53,77,85,86,93 No study reported data on symptomatic proximal or
distal DVT, but 8 studies reported on any proximal DVT,37,78,79,82,84,85,92,93
and 7 studies reported on any distal DVT.37,77,79,82,85,92,93
The EtD framework is available online at https://guidelines.gradepro.org/
profile/61E7ADC1-4C91-8D58-9E3A-56BFEE3EAC20.
Benefits. There may be no difference in mortality between
mechanical prophylaxis and no prophylaxis (RR, 1.33; 95% CI,
0.71-2.51; low certainty in the evidence of effects); this corresponds
to 6 more (5 fewer to 28 more) deaths per 1000 patients. There may
be a small difference in symptomatic PEs (RR, 0.61; 95% CI, 0.27-
1.40; low certainty in the evidence of effects) corresponding to 3
fewer (6 fewer to 3 more) symptomatic PEs per 1000 patients based
on a baseline risk of 0.8% and 4 fewer (8 fewer to 4 more) per 1000
patients based on a baseline risk of 1.1% from observational data.73
There may be no difference in symptomatic proximal DVTs (RR, 0.75;
95% CI, 0.35-1.61; very low certainty in the evidence of effects), but
we are uncertain of this. The risk of symptomatic distal DVTs may be
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reduced (RR, 0.66; 95% CI, 0.50-0.86; very low certainty in the
evidence of effects), but we are uncertain of this.
Harms and burden. There were no relevant adverse events
deemed critical for this comparison. The panel was unable to
assess the relative effect of mechanical prophylaxis on potential
hazards, such as falls or skin complications.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, imprecision, and inconsistency.
Other EtD criteria and considerations. The panel deter-
mined that there was possibly important uncertainty or variability in
how much affected individuals valued the main outcomes. They
further judged that the balance between desirable and undesir-
able effects probably favors mechanical prophylaxis over no
prophylaxis for patients at moderate or high risk for VTE but
not patients at low risk for VTE. The panel judged the costs
associated with mechanical prophylaxis to be moderate based
on very low certainty in the evidence about resource requirements,
with no available studies explicitly addressing this question. Cost-
effectiveness probably favors mechanical prophylaxis. There would
probably be no impact on health equity; mechanical prophylaxis
would probably be acceptable to stakeholders and probably
feasible to implement. The panel recognized that many patients
considered at moderate to high risk for VTE would receive
pharmacological prophylaxis in addition to mechanical methods.
The guideline panel determined that there was very low certainty
evidence for a net health benefit/harm for mechanical pro-
phylaxis. Most of the evidence comes from orthopedics (elective
hip and knee arthroplasty). In settings where intermittent
pneumatic compression is not available, the use of stockings
as mechanical prophylaxis is an acceptable and feasible option
(see Recommendation 3).
Conclusions and research needs for this recommendation.
For patients undergoing major surgery and at risk for VTE, the ASH
guideline panel suggests using mechanical prophylaxis over
no mechanical prophylaxis, recognizing that the certainty in the
evidence is very low for this recommendation.
The panel recognizes that there is a need for high-quality
clinical trials using clinically relevant end points to improve the
certainty of the evidence supporting this recommendation,
particularly outside the orthopedic setting. However, this is
likely a lower priority for research than studies evaluating
mechanical prophylaxis in combination with pharmacological
prophylaxis.
Question: Should pneumatic compression devices vs graduated
compression stockings be used for patients undergoing major
surgery?
Recommendation 3
For patients undergoing major surgery who receive mechanical
prophylaxis, the ASH guideline panel suggests using in-
termittent compression devices over graduated compression
stockings (conditional recommendation based on very low
certainty in the evidence of effects Å◯◯◯).
Summary of the evidence. We identified 6 systematic reviews
addressing this question.25-28,31,32 We identified 11 studies in these
reviews that fulfilled our inclusion criteria and measured outcomes
relevant to this context.37,94-103 Our systematic search of RCTs did not
identify any additional study that fulfilled the inclusion criteria.
Five studies reported the effect of pneumatic compression prophylaxis
compared with graduated compression stockings prophylaxis on
risk of mortality.94,96,97,101,102 Eight studies reported the effect on
the development of symptomatic PEs,37,95-99,102,103 and 4 studies
reported the effect on any PE.94,100,101,103 One study reported data
on symptomatic proximal and symptomatic distal DVTs,98 whereas
6 studies reported on any proximal DVT,37,94,96,98-100 and 5 studies
reported on any distal DVT.37,94,96,98,100
The EtD framework is available online at https://guidelines.grade-
pro.org/profile/1584FD2F-9CC6-9C59-8DF5-48F0045F1BE5.
Benefits. There is no difference in mortality between pneumatic
compression and graduated compression stockings prophylaxis
(RR, 1.04; 95% CI, 0.16-6.63; low certainty in the evidence of
effects); this corresponds to 2 more (41 fewer to 274 more) per
1000 patients. There may also be no difference in symptomatic PEs
(RR, 0.56; 95% CI, 0.17-1.86; low certainty in the evidence of
effects). The risk of symptomatic proximal DVTs may be reduced
(RR, 0.48; 95% CI, 0.25-0.93, very low certainty in the evidence of
effects), but we are uncertain of this finding. This benefit likely
corresponds to 9 fewer (1-12 fewer) symptomatic proximal DVTs in
1000 patients with a baseline risk of 1.6% and 14 fewer (2-20
fewer) symptomatic proximal DVTs per 1000 patients based on a
baseline risk of 2.6% from observational data.73 The risk of distal
DVT (RR, 0.55; 95% CI, 0.25-1.22, very low certainty in the
evidence of effects) appears to be similar, but we are uncertain of
this finding.
Harms and burden. There were no relevant adverse events
deemed critical for this comparison. Potential harms included
reduced mobility, and pneumatic compression prophylaxis may be
uncomfortable. There is also a small risk for inappropriate use of
pneumatic compression prophylaxis for some patients (eg, those with
lower extremity fractures).
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, imprecision, and inconsistency.
Other EtD criteria and considerations. The panel deter-
mined that there was possibly important uncertainty or variability in
how much affected individuals valued the main outcomes. They
further judged that the balance between desirable and undesirable
effects probably favors pneumatic compression prophylaxis over
graduated compression stockings prophylaxis. The panel was
unable to assess the relative effect of pneumatic compression
compared with that of graduated compression stockings on the risk of
other hazards, such as falls or skin complications. These might be
considered “unmeasured harms” of mechanical prophylaxis. The panel
judged the costs associated with pneumatic compression prophylaxis
to be moderate based on very low certainty in the evidence about
resource requirements, with no available studies explicitly address-
ing this question. Cost-effectiveness probably favors pneumatic
compression prophylaxis. There would probably be no impact on
health equity; pneumatic compression prophylaxis would probably
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be acceptable to stakeholders and probably feasible to implement.
Lack of information regarding out-of-hospital use of pneumatic
compression was a limitation of this technique. The panel recognizes
that most of the evidence about the effectiveness comes from
orthopedics (elective hip and knee arthroplasty).
Conclusions and research needs for this recommendation.
The panel suggests using pneumatic compression devices over
graduated compression stockings for patients undergoing major
surgery, recognizing that there was very low certainty evidence for a
net health benefit/harm. The recommendation applies to patients
undergoing major surgery who are considered at risk for VTE.
In settings where pneumatic compression devices are not avail-
able, the use of graduated compression stockings is reasonable,
because mechanical prophylaxis is an acceptable and feasible
option. Further well-designed studies using clinically relevant end
points are required to improve the quality of evidence related to
this question. Studies outside the field of orthopedics would be
particularly useful.
Question: Should combined pharmacological and mechanical
prophylaxis vs pharmacological prophylaxis alone be used for
patients undergoing major surgery?
Recommendation 4
For patients undergoing major surgery who receive pharma-
cologic prophylaxis, the ASH guideline panel suggests using
combined prophylaxis with mechanical and pharmacological
methods over prophylaxis with pharmacological agents alone
(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯). Remark: For patients considered
at high risk for VTE, combined prophylaxis is particularly favored
over mechanical or pharmacological prophylaxis alone.
Summary of the evidence. We identified 7 systematic reviews
addressing this question.23-26,28,29,31-33 We identified 19 studies in these
reviews that fulfilled our inclusion criteria and measured outcomes
relevant to this context.36,60,62,68,70,104-117 Our systematic search of
RCTs did not identify any additional study that fulfilled the inclusion
criteria.
Seven studies reported the effect of the combination of pharma-
cological and mechanical prophylaxis compared with pharmaco-
logical prophylaxis alone on the risk of mortality.36,60,62,68,104,105,107
Ten studies reported the effect on the development of symptomatic
PEs,60,62,68,70,105,107,109-111,117 and 6 studies reported the effect
on any PE.36,104,108,112,116,117 Three studies reported data on
symptomatic proximal DVTs,62,70,112 and 8 studies reported data on
any proximal DVT.62,70,104,108,112-114 Three studies reported data
on symptomatic distal DVTs,70,105,112 and 7 studies reported on any
distal DVT.68,105,108,109,112-114 Six studies reported the effect of
combination pharmacological and mechanical prophylaxis com-
pared with pharmacological prophylaxis alone on the risk of major
bleeding,60,62,68,104,109,112 and 2 studies reported the effect on the
risk of reoperation.107,117
The EtD framework is available online at https://guidelines.gradepro.org/
profile/9AC669C6-30BB-C8DF-8430-3EDA0D4842C8.
Benefits. There may be no difference in mortality between
pharmacological prophylaxis combined with mechanical prophy-
laxis and pharmacological prophylaxis alone (RR, 0.29; 95% CI,
0.06-1.38; low certainty in the evidence of effects); this
corresponds to 5 fewer (7 fewer to 3 more) deaths per 1000
patients. There may be a reduction in symptomatic PEs (RR,
0.40; 95% CI, 0.25-0.65; low certainty in the evidence of effects)
favoring combined prophylaxis. Depending on the baseline risk, this
benefit likely corresponds to 5 fewer (3-6 fewer) per 1000 patients
with a baseline risk of 0.8% to up to 7 fewer (4-8 fewer) per 1000
patients based on a baseline risk of 1.2% from observational data.73
We are very uncertain whether the risks of symptomatic proximal
DVTs (RR, 0.14; 95% CI, 0.01-2.63; very low certainty in the
evidence of effects) and symptomatic distal DVTs (RR, 1.99; 95%
CI, 0.35-11.33; very low certainty in the evidence of effects) differ
between the 2 groups.
Harms and burden. Rates of major bleeding may be similar (RR,
1.05; 95%CI, 0.32-3.40; low certainty in the evidence of effects),
corresponding to 0 fewer (5 fewer to 17 more) events per 1000
patients. We were unable to estimate the RR of major reoperation
given that there were no events in either group in the 2 included
trials.107,117
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
for study limitations and imprecision.
Other EtD criteria and considerations. The panel deter-
mined that there was possibly important uncertainty or variability in
how much affected individuals valued the main outcomes. They
further judged that the balance between desirable and undesirable
effects probably favors combined pharmacological and mechanical
prophylaxis over pharmacological prophylaxis alone. The panel was
unable to assess the impact of adding mechanical prophylaxis on
the risk of other outcomes, such as falls or skin complications.
These might be considered “unmeasured harms” of mechanical
prophylaxis. The panel judged the costs associated with combined
prophylaxis to be moderate based on very low certainty in the
evidence about resource requirements. Cost-effectiveness proba-
bly favors combined pharmacological and mechanical prophylaxis.
There would probably be no impact on health equity; combined
pharmacological and mechanical prophylaxis would probably be
acceptable to stakeholders and probably feasible to implement.
The panel determined that there was very low certainty evidence
for a net health benefit/harm for combined pharmacological and
mechanical prophylaxis over pharmacological prophylaxis alone.
Most of the evidence evaluating this question comes from the
orthopedic (joint arthroplasty) setting.
Conclusions and research needs for this recommendation.
The guideline panel suggests using combined pharmacological
and mechanical prophylaxis over pharmacological prophylaxis
alone for patients undergoing major surgery, based on very low
certainty in the evidence of effects. The panel judged that com-
bined pharmacological and mechanical prophylaxis would be most
beneficial for patients considered at very high risk for VTE following
major surgery.
Further high-quality research studies using clinically important
outcomes comparing combination pharmacological and mechani-
cal methods with pharmacological methods alone are required
to provide greater certainty about this recommendation. Studies
addressing this question outside the orthopedic setting are most
needed.
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Question: Should mechanical prophylaxis combined with pharma-
cological prophylaxis vs mechanical prophylaxis alone be used for
patients undergoing major surgery?
Recommendation 5
For patients undergoing major surgery, the ASH guideline
panel suggests using combined mechanical and pharmaco-
logical prophylaxis or mechanical prophylaxis alone, depending
on the risk of VTE and bleeding based on the individual patient
and the type of surgical procedure (conditional recommenda-
tion based on low certainty in the evidence of effects ÅÅ◯◯).
Remark: For patients considered at high risk for VTE, com-
bined prophylaxis is particularly favored over mechanical or
pharmacological prophylaxis alone.
Summary of the evidence. We identified 7 systematic reviews
addressing, in part, this question.23-26,29,32,33 We identified 19
studies in these reviews that fulfilled our inclusion criteria and
measured outcomes relevant to this context.36,60,62,68,118-132 Our
systematic search of RCTs identified 5 additional studies that
fulfilled the inclusion criteria.70,72,133-136
Fourteen studies reported the effect of combined mechanical and
pharmacological prophylaxis compared with mechanical prophylaxis
alone on the risk of mortality.36,60,62,68,120,121,124,125,127,128,130,133,134,136
Sixteen studies reported the effect on the development of
symptomatic PEs,60,62,70,120-131,134 and 11 studies reported on
the effect on any PEs36,118,120,121,126,128,130,131,133,135,136 Six
studies reported data on symptomatic DVTs,62,70,120,127,128,131 and 10
studies reported data on any proximal DVT.62,70,120-122,124,125,127,128,130
Five studies reported data on symptomatic distal DVTs,70,120,127,128,131
and 14 studies reported on any distal DVT.118,120-122,124,125,127,128,130
Fifteen studies reported the effect of combined mechanical
and pharmacological prophylaxis on the risk of major
bleeding,60,62,68,118,119,121,123-125,127,128,130,134-136 and 4 studies
reported the effect on the risk of reoperation.118,125,134,135
The EtD framework is available online at https://guidelines.gradepro.org/
profile/75138F44-7AFE-A008-A8BD-10DD1DFD5377.
Benefits. There is likely no difference in mortality between
combined prophylaxis and mechanical prophylaxis alone (RR, 1.24;
95% CI, 0.67-2.30; moderate certainty in the evidence of effects),
corresponding to 3 more (4 fewer to 17 more) deaths per 1000
patients. There is likely a reduction in symptomatic PEs (RR, 0.34;
95% CI, 0.13-0.90; moderate certainty in the evidence of effects)
favoring combined prophylaxis. Depending on the baseline risk,
assumed to be 0.8% or 1.1% based on a large observational
study,73 this benefit likely corresponds to 5 fewer (1-7 fewer) per
1000 patients in a lower-risk population to 7 fewer (1-10 fewer) per
1000 patients in a higher-risk population. The risk of symptomatic
proximal DVT (RR, 0.71; 95% CI, 0.07-6.75; low certainty in the
evidence of effects) and symptomatic distal DVT (RR, 0.38;
95% CI, 0.06-2.42; low certainty in the evidence of effects) may
be similar between the 2 interventions, irrespective of the
baseline risk group.
Harms and burden. Combined prophylaxis likely results in a
small increased risk for major bleeding (RR, 2.23; 95% CI, 1.09-
4.57; moderate certainty in the evidence of effects). This likely
corresponds to 14 more (1-42 more) per 1000 patients. Rates of
major reoperation may be similar (RR, 2.96; 95% CI, 0.73-12.05;
low certainty in the evidence of effects) between the 2
interventions, corresponding to 4 more (1 fewer to 21 more)
per 1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
for study limitations and imprecision.
Other EtD criteria and considerations. The panel judged
that the balance between desirable and undesirable effects does
not favor combined pharmacological and mechanical prophylaxis
vs mechanical prophylaxis alone. Instead, the balance between
desirable and undesirable effects will depend upon the risk of
VTE and bleeding based on the individual patient and the type of
surgical procedure. The panel judged the costs associated with
combined prophylaxis to be moderate based on very low certainty
in the evidence about resource requirements. The panel determined
that there was possibly important uncertainty or variability in how much
affected individuals valued the main outcomes. Cost-effectiveness
varies based on the underlying VTE and bleeding risk categories. There
would probably be no impact on health equity, and combined
prophylaxis and mechanical prophylaxis alone would be acceptable
to stakeholders and probably feasible to implement.
Conclusions and research needs for this recommendation.
The guideline panel suggests using combined mechanical and
pharmacological prophylaxis or mechanical prophylaxis alone
for patients undergoing major surgery (based on low certainty in
the evidence of effects). The balance of effects was considered
dependent upon the risk of VTE and bleeding. Therefore, it is
important to establish the baseline risk for VTE and major bleeding
in surgical patients. For patients considered at high thrombosis risk
and low bleeding risk, combined mechanical and pharmacological
prophylaxis should be considered. For patients at high bleeding risk,
mechanical prophylaxis methods alone may be preferred.
Further high-quality research studies using clinically important
outcomes to identify patients with high baseline risk for VTE in whom
combined pharmacological and mechanical prophylaxis would be of
value, particularly outside the orthopedic setting, are needed.
Prophylactic insertion of an IVC filter. Question: Should
insertion of an IVC filter vs no IVC filter be used for VTE prophylaxis
for patients undergoing major surgery?
Recommendation 6
For patients undergoing major surgery, the ASH guideline
panel suggests against using IVC filters for prophylaxis of VTE
(conditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯).
Summary of the evidence. We identified 2 systematic reviews
of RCTs and observational studies137,138 that addressed this
research question in bariatric surgery and trauma patients. We
identified 14 studies139-152 in these reviews that fulfilled our
inclusion criteria and measured outcomes relevant to this
context. Our search for RCTs and observational studies
identified 1 additional study that fulfilled the inclusion criteria.153
Additionally, we identified 1 systematic review of RCTs and
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observational studies that was published after our initial
literature search, which did not include any new study not
already included in our meta-analysis.154 We also identified 1
RCT published in July 2019, evaluating the use of IVC filters for
patients experiencing trauma.155 Although we did not update
the meta-analysis, the trial results were assessed by the panel as
consistent with the recommendation.
Of the 15 studies included in the meta-analysis, 1 was an RCT.150
Twelve of the studies reported the effect of IVC filters on the risk of
mortality.139,143-147,149-153 Five studies assessed the development
of symptomatic PEs,142,149,150,152,153 and 10 studies assessed the
development of any PE.139-141,143-148,151 Ten studies assessed the
development of DVTs,139,141,143,144,146-148,150,151,153 with 1 study
assessing the development of symptomatic DVTs specifically141 and
1 study assessing the development of proximal DVTs specifically.153
The EtD framework is available online at https://guidelines.gradepro.org/
profile/4885EDB9-B445-5554-BD62-CFE2EED6D08E.
Benefits. IVC filter use may increase mortality slightly (RR, 1.38;
95% CI, 0.81-2.37; very low certainty in the evidence of effects),
although the confidence interval was wide and included the
possibility of no increase. Overall, we are very uncertain of this
finding. Based on the control group event rate of 1.1% in this meta-
analysis, this would correspond to 4 more deaths (2 fewer to 15
more) per 1000 patients receiving an IVC filter following major
surgery or trauma. IVC filters may reduce the risk of symptomatic PE
following major surgery and trauma (RR, 0.29; 95% CI, 0.11-0.80;
very low in the evidence of effects), but we are very uncertain about
this finding. Based on a baseline risk of 0.8% from observational
data,73 this corresponds to 6 fewer (2-7 fewer) symptomatic PEs.
Based on a higher baseline risk of 1.1%,73 this could result in 8
fewer PEs (2-10 fewer) per 1000 patients receiving an IVC filter;
however, this is very uncertain. Rates of symptomatic proximal DVT
may be increased with use of IVC filters (RR, 2.19; 95% CI, 1.07-
4.50; very low certainty in the evidence of effects), but we are
once again very uncertain of this finding. This corresponds to 20
more (1-58 more) or 31 more (2-92 more) per 1000 patients,
based on baseline risks of 1.6% and 2.6%, respectively, from
observational data.73 We are also uncertain whether rates of
symptomatic distal DVT are increased (RR, 2.72; 95% CI, 1.41-
5.21; very low certainty in the evidence of effects), corresponding to
2 more (1-6 more) to 4 more (1-9 more) per 1000 patients, based
on baseline risks of 0.1% and 0.2%, respectively, from observa-
tional data.73
Harms and burden. The panel did not consider potential harms
of IVC filters beyond VTE. These potential harms would include
potentially severe complications, such as IVC perforation and IVC
filter embolization.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, inconsistency, and indirectness.
Other EtD criteria and considerations. The panel deter-
mined that there was possibly important uncertainty or variability in
how much affected individuals might value the main outcomes. They
judged that the balance between desirable and undesirable effects
favored not using IVC filters in the setting of major surgery or
trauma. The panel judged from our analysis of data, largely from
observational studies, that the high rates of DVT and the trend for
higher mortality associated with the use of IVC filters outweighed
the potential reduction in PEs. Furthermore, a recently published
high-quality RCT of IVC filters, following major trauma for patients
in whom pharmacological prophylaxis was considered contra-
indicated, did not find that IVC filters reduced symptomatic PE or
death.155 Given there are serious nonthrombotic risks associated
with IVC filters (eg, IVC perforation and IVC filter embolization) that
were not considered in our analysis, this would further strengthen
our recommendation against IVC filter use.156
The panel also recognized that the cost of IVC filters and resources
associated with their insertion were large. The panel concluded that
routine use of IVC filters following major surgery or trauma was
probably not cost-effective and favored not placing a filter. Because of
the increased resources required, high costs, and limited availability of
interventional radiology units, health equity would probably be reduced
by use of IVC filters. Routine use of IVC filters might also not be
acceptable or feasible to implement for some stakeholders.
Conclusions and research needs for this recommendation.
The panel suggests against using IVC filters for prophylaxis of
VTE for patients undergoing major surgery or trauma patients
based upon very low certainty in the evidence. The very low quality
evidence underlying this recommendation supports the need for
well-designed RCTs evaluating clinically important outcomes to
better define the role of IVC filters for patients who cannot safely
or feasibly receive pharmacological or mechanical prophylaxis
following major surgery or trauma. Further studies quantifying the
nonthrombotic risks of IVC filters would also be of value.
Timing of antithrombotic prophylaxis
Question: Should extended antithrombotic prophylaxis vs short-
term antithrombotic prophylaxis be used for patients undergoing
major surgery?
Recommendation 7
For patients undergoing major surgery, the ASH guideline
panel suggests using extended antithrombotic prophylaxis over
short-term antithrombotic prophylaxis (conditional recommen-
dation based on very low certainty in the evidence of effects
Å◯◯◯). Remark: Extended prophylaxis was generally
considered as beyond 3 weeks (range: 19-42 days), and
short-term prophylaxis was considered as up to 2 weeks
(range: 4-14 days).
Summary of the evidence. We identified 9 systematic
reviews addressing this research question.157-165 We identified
14 studies166-179 in these reviews that fulfilled our inclusion criteria
and measured outcomes relevant to this context. Our systematic
search of RCTs identified 6 additional studies180-185 not included in
previous systematic reviews that fulfilled the inclusion criteria.
Seventeen studies reported the effect of extended vs short-term
duration of pharmacological thromboprophylaxis on the develop-
ment of mortality,166,167,170-173,175-185 17 studies reported the effect
on the development of PEs,166,167,170-184 18 studies reported the
effect on the development of proximal DVTs,166-173,175-184
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14 studies reported the effect on the development of distal
DVTs,166,169,171-173,175,177-184 16 studies reported the effect
on the risk of major bleeding,167-173,177-185 and 6 studies reported
the effect on the risk of reoperation.166,173,174,179,184,185 In general,
these studies compared shorter courses of pharmacological
prophylaxis (4-14 days) with extended courses of pharmacological
prophylaxis (19-42 days) and then followed patients for a common
period (3-9 months) for VTE and bleeding complications.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/79bce70d-c689-4fbf-b0e4-c2ec3142bb2c.
Benefits. There is likely no difference in mortality between
extended- and standard-course antithrombotic prophylaxis (RR,
0.94; 95% CI, 0.64-1.39; moderate certainty in the evidence of
effects); this corresponds to 1 fewer death (6 fewer to 6 more)
per 1000 patients. There is likely a small reduction in
symptomatic PEs (RR, 0.44; 95% CI, 0.22-0.85; moderate
certainty in the evidence of effects). Depending on baseline risk,73
this corresponds to 4 fewer (1-6 fewer) deaths per 1000 patients
with a baseline risk of 0.8% and 6 fewer (2-9 fewer) deaths per
1000 patients with a baseline risk of 1.1% receiving extended
pharmacological prophylaxis. Symptomatic proximal DVTs are
also likely reduced (RR, 0.30; 95% CI, 0.21-0.42; moderate
certainty in the evidence of effects). Depending upon the
baseline risk,73 this corresponds to 12 fewer (10-13 fewer)
symptomatic proximal DVTs per 1000 patients in a lower-risk
group of patients with a 1.6% baseline risk or 18 fewer (15-21
fewer) per 1000 patients in a higher-risk group with a 2.6%
baseline risk. Extended pharmacological prophylaxis likely
reduces distal DVTs (RR, 0.57; 95% CI, 0.37-0.87; moderate
certainty in the evidence of effects), which corresponds to 1
fewer (0-1 fewer) symptomatic distal DVT per 1000 patients
based on a 0.1% baseline risk from observational data.73
Harms and burden. Rates of major bleeding may be similar (RR,
1.00; 95% CI, 0.59-1.70; low certainty in the evidence of effects),
corresponding to 0 fewer (3 fewer to 6 more) per 1000 patients.
Rates of reoperation may also be similar (RR, 0.82; 95% CI, 0.34-
1.99; very low certainty in the evidence of effects), but we are very
uncertain about this finding.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the
lowest certainty in the evidence for the critical outcomes,
downgrading for study limitations and very serious imprecision.
Other EtD criteria and considerations. The panel deter-
mined that there was possibly important uncertainty or variability
in how much affected individuals valued the main outcomes.
They further judged that the balance between desirable and
undesirable effects probably favors extended-duration vs
standard-duration prophylaxis. The panel judged the costs
associated with extended-duration prophylaxis to be moderate
based on very low certainty in the evidence. Cost-effectiveness
probably favors extended-duration prophylaxis. Health equity is
possibly reduced with extended-duration prophylaxis, with
economically disadvantaged patients potentially being unable
to afford the required medications or medication copayments.
Extended-duration prophylaxis would probably be acceptable to
stakeholders and probably feasible to implement. The panel
recognized that most of the trials compared a prolonged pro-
phylaxis (up to 42 days, or ;6 weeks following surgery) with a
short duration of anticoagulant prophylaxis designed to approxi-
mate the length of a postoperative hospital stay (;4-14 days) in
the eras in which the studies were performed. Furthermore, the
panel recognized that these studies were largely limited to 2 high-
risk surgical scenarios (total hip or knee arthroplasty and major
cancer general surgical procedures).
Conclusions and research needs for this recommendation.
The guideline panel determined that the net benefit favored using
extended-course antithrombotic prophylaxis over short-term antith-
rombotic prophylaxis for patients undergoing major surgery based
on very low certainty evidence. Given the very low certainty in the
evidence of effects this is based upon, there is a critical need for
higher-quality studies comparing extended vs short-term prophylaxis
using clinically important outcomes in contemporary surgical practices,
which are marked by early patient mobilization and shorter hospital
stays. There is particularly a need for studies outside the general
hip and knee arthroplasty and cancer general surgical settings to
confirm the benefits of extended prophylaxis in other settings.
There also appears to be a need for further research to determine
the optimal duration of extended prophylaxis.
Question: Should early vs delayed antithrombotic prophylaxis be
used for patients undergoing major surgery?
Recommendation 8
For patients undergoing major surgery, the ASH guideline panel
suggests using early or delayed antithrombotic prophylaxis (con-
ditional recommendation based on very low certainty in the evi-
dence of effectsÅ◯◯◯).Remark: Twelve hours following surgery
was arbitrarily selected to be the cutoff point between early and
late postoperative antithrombotic administration.
Summary of the evidence. We did not find any systematic
reviews that addressed this question. In our systematic search of the
literature we found 6 studies that fulfilled our inclusion criteria and
measured outcomes relevant to this context.186-191 We cross-
referenced the studies found in our search with the references from a
recent narrative review192 but did not identify any additional studies
that fulfilled our inclusion criteria. All studies included surgical patients.
Twelve hours was selected to be the cutoff point between early and
late postsurgical antithrombotic administration. Six studies186-191
reported the effect of early vs late postsurgical antithrombotic
administration on the risk of mortality and on the risk of development
of any PEs. Five studies186,188-191 reported the effect on the risk of any
proximal and any distal DVTs, and 1 reported the effect on the risk of
any DVT.187 Only the 5 studies that specified the location of the DVT
were included in the evidence profile. Six studies186-191 reported the
effect of early vs late postsurgical antithrombotic administration on the
risk of major bleeding and on the risk of reoperation.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/E664E38D-FA7C-DBC9-8E77-373D0582050E.
Benefits. Early prophylaxis may result in no difference in mortality
(RR, 1.57; 95% CI, 0.77-3.19; very low certainty in the evidence of
effects), but we are very uncertain about this finding. This
corresponds to 1 more (1 fewer to 6 more) per 1000 patients.
We are uncertain about the effect of early prophylaxis on
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symptomatic PEs (RR, 0.63; 95% CI, 0.23-1.72; very low certainty
in the evidence of effects); depending on the baseline risk from
observational data,73 this corresponds to 3 fewer (6 fewer to 6
more) to 4 fewer (8 fewer to 8 more) per 1000 patients with
baseline risks of 0.8% and 1.1%, respectively. We are also uncertain
of the effect of early prophylaxis on symptomatic proximal DVTs (RR,
0.88; 95%CI, 0.40-1.96; very low certainty in the evidence of effects),
corresponding to 2 fewer (10 fewer to 16 more) to 3 fewer (16 fewer
to 25 more) per 1000 patients when applying baseline risks of 1.6%
and 2.6%, respectively.73 Early prophylaxis has an uncertain effect on
distal DVTs (RR, 0.68; 95% CI, 0.41-1.12; very low certainty in the
evidence of effects), with an absolute risk reduction from 0 fewer (0-1
fewer; baseline risk, 0.1%73) to 1 fewer (0-1 fewer; baseline risk, 0.2%
73) symptomatic distal DVT per 1000 patients.
Harms and burden. The risk of major bleeding may be similar
(RR, 1.63; 95% CI, 0.81-3.29; very low certainty in the evidence of
effects), corresponding to 5 fewer (1 fewer to 17 more), although
we are very uncertain of this finding. Also, the need for reoperation
may be increased (RR, 1.84; 95% CI, 0.89-3.80; very low certainty
in the evidence of effects) corresponding to 2 more reoperations (0
fewer to 6 more) per 1000 patients. Once again, we are very
uncertain about this finding.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes and downgrading for
study limitations, indirectness, and imprecision.
Other EtD criteria and considerations. Based on very low
certainty in the evidence of effects, the panel judged that the
balance of effects did not favor early or delayed institution of
pharmacological antithrombotic prophylaxis in major surgical
patients. Costs and saving would likely be negligible, and the panel
saw no particular issues related to equity, acceptability, or feasibility.
Conclusions and research needs for this recommendation.
The guideline panel suggests early administration (postoperative,
within 12 hours) or late administration (postoperative, after 12 hours)
of antithrombotic prophylaxis in major surgical patients, based on
very low certainty in the evidence of effects. In light of the very low
certainty in the evidence of effects, further high-quality studies using
clinically important outcomes are important to provide greater certainty
about the benefits and risks of early pharmacological prophylaxis.
The panel was particularly interested in seeing future high-quality
studies of early vs late pharmacological prophylaxis studies in
high-risk bleeding patients, examining the benefits and risks of later
intervention (days following surgery) once the bleeding risk had
greatly subsided.
Orthopedic surgery
Question: Should ASA vs anticoagulants be used for patients
undergoing total hip or knee arthroplasty?
Recommendation 9
For patients undergoing total hip arthroplasty or total knee
arthroplasty, the ASH guideline panel suggests using ASA or
anticoagulants (conditional recommendation based on very low
certainty in the evidence of effects Å◯◯◯).
Summary of the evidence. We found 7 RCTs that compared
the use of ASA vs anticoagulants for patients undergoing total hip
arthroplasty or total knee arthroplasty.193-199 Additionally, we
identified 2 trials comparing ASA with LMWH in total hip
arthroplasty patients200 and ASA with DOAC in total hip
arthroplasty or total knee arthroplasty patients,201 in which all
participants received a 10-day period of LMWH or a 5-day period of
DOACs, respectively, prior to randomization. The trials were reviewed
by the panel but were not included in the main meta-analysis
because of differences in the comparator groups. Of the 7 studies
included in the analysis, 2 studies compared ASA with UFH,193,195
4 studies compared ASA with LMWH,194,196,198,199 and 2 studies
compared ASA with oral anticoagulants.197,199 All 7 studies
reported the outcomes of mortality and PE,193-199 6 studies
reported on proximal and distal DVTs,195-199 and 5 studies reported
on major bleeding.194-196,198,199 We found no studies addressing
the outcome of reoperation.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/3532ED1D-6A40-A982-BC3F-6DA318B3B611.
Benefits. There may be no difference in mortality between ASA and
anticoagulants (RR, 2.32; 95% CI, 0.15-36.90; low certainty in the
evidence of effects). There also may be no difference in the risk of
symptomatic PEs between ASA and anticoagulants (RR, 1.49; 95%CI,
0.37-6.09; very low certainty in the evidence of effects), corre-
sponding to 3 more (4 fewer to 29 more) symptomatic PEs per
1000 patients based on a baseline risks of 0.6%202,203 from
observational data; however, we are very uncertain of this finding.
There also may be no difference in the risk of proximal DVTs (RR,
1.49; 95% CI, 0.51-4.34; very low certainty in the evidence of
effects), corresponding to 3 more symptomatic (3 fewer to 30
more) proximal DVTs per 1000 patients based on a baseline risk of
0.6%,202,203 or in the risk of distal DVTs (RR, 1.45; 95% CI, 0.86-
2.46; very low certainty in the evidence of effects), corresponding
to 0 fewer symptomatic distal DVTs (0 fewer to 1 more) per 1000
patients based on a baseline risk of 0.05%,202,203 although we were
very uncertain about both findings.
Harms and burden. ASA may lead to a small increased risk for
major bleeding (RR, 2.63; 95% CI, 0.64-10.79; low certainty in the
evidence of effects). These findings correspond to 6 more (1 fewer
to 35 more) major bleeding events per 1000 patients. We found no
evidence to inform the comparative risk of reoperation.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
for study limitations, indirectness, and imprecision.
Other EtD criteria and considerations. The panel deter-
mined that there was probably important uncertainty or variability
in how much affected individuals value the main outcomes. It
further judged that use of ASA saved costs and resources;
however, the results of cost-effectiveness studies varied, with some
favoring ASA and others favoring anticoagulant prophylaxis.
Health equity would probably be increased as a consequence of
the use of ASA. Acceptability was thought to also vary depending
on the type of stakeholder (patient vs health care provider). There
were no concerns about the feasibility of implementation. A recent
large RCT supports our recommendation that ASA or anticoagu-
lants be used for VTE prophylaxis following total hip or knee
arthroplasty. However, this study was not included in our analysis
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because all patients received a 5-day course of a DOAC before
being randomized to ASA or to stay on a DOAC for extended
prophylaxis.201
Conclusions and research needs for this recommendation.
The guideline panel suggests using ASA or anticoagulants for
patients undergoing total hip arthroplasty or total knee arthro-
plasty (conditional recommendation based on very low certainty
in the evidence of effects). They determined that there was very
low certainty evidence for any net health benefit/harm from using
ASA vs anticoagulants. Of 8 panel members who voted on this
recommendation, 5 voted for recommending either interven-
tion, and 3 voted for a conditional recommendation in favor of
anticoagulants.
The panel identified that there is a need for large well-designed
clinical trials using clinically important end points comparing ASA
with other pharmacological methods following total hip and knee
arthroplasty. The panel noted that such studies are underway.
Question: Should DOACs vs LMWH be used for patients
undergoing total hip or knee arthroplasty?
Recommendation 10
For patients undergoing total hip arthroplasty or total knee
arthroplasty in which anticoagulants are used, the ASH
guideline panel suggests using DOACs over LMWH (con-
ditional recommendation based on moderate certainty in the
evidence of effects ÅÅÅ◯).
Summary of the evidence. We identified 1 systematic re-
view204 that addressed this question. Twenty-two studies in this
review fulfilled our inclusion criteria. Our update of the systematic
review identified 16 additional studies. All studies included patients
undergoing elective hip or knee replacement.
Five studies assessed the effects of dabigatran,191,205-208 15 studies
assessed the effects of rivaroxaban,180,185,189,190,199,209-218 4
studies assessed the effects of apixaban,219-222 5 studies
assessed the effects of darexaban223-226 and edoxaban,227-231
and 4 studies assessed the effects of other DOACs.232-235
Thirty-four studies reported mortality,180,185,189-191,199,205-215,218-222,
224-231,233-235 whereas 33 studies reported nonfatal PEs.180,185,189-191,
199,205-212,214-216,219-222,224-231,233-235 We estimated proximal and
distal DVTs using the pooled estimate from symptomatic DVTs, which
was reported in 30 studies.185,189-191,199,205-212,214-216,219-222,224-230,
234,235 Thirty-two studies reported major bleeding,180,185,189-191,205-212,
214,215,219-222,224-235 whereas only 15 studies reported bleeding
leading to reoperation.180,185,189-191,205-207,209-212,215,220,221
We tested potential differences in the effects with specific drugs
and between classes (anti–factor IIa vs anti–factor Xa). We found
no interaction for any of the outcomes. Additionally, we conducted a
sensitivity analysis excluding dose-finding studies. The results did
not change appreciably.
The EtD framework is available online at https://guidelines.gradepro.
org/profile/9160FAA2-4F98-A3AA-9816-64DF796ABBC7.
Benefits. DOACs probably do not reduce mortality compared
with that associated with LMWH (RR, 0.94; 95% CI, 0.53-1.66;
moderate certainty in the evidence of effects); this corresponds to
0 fewer deaths (1 fewer to 1 more) per 1000 patients. DOACs
probably slightly reduce the rate of symptomatic PEs (RR, 0.74;
95% CI, 0.50-1.10; moderate certainty in the evidence of effects);
based on a baseline risk of 0.6% from observational data,202,203 this
corresponds to 1 fewer (3 fewer to 1 more) symptomatic PE per
1000 patients. The use of DOACs reduces symptomatic proximal
DVTs slightly (RR, 0.56; 95% CI, 0.39-0.79; high certainty in the
evidence of effects), which corresponds to 3 fewer (1-4 fewer)
symptomatic proximal DVTs per 1000 patients, based on a base-
line risk of 0.6% from observational data.202,203 This effect on
symptomatic distal DVTs is probably not clinically relevant (RR, 0.56;
95% CI, 0.39-0.79; high certainty in the evidence of effects), which
corresponds to 0 fewer symptomatic distal DVTs per 1000 patients
based on a baseline risk of 0.049%, from observational data.202,203
Harms and burden. DOACs probably do not increase major
bleeding compared with LMWH (RR, 1.03; 95% CI, 0.79-1.35;
moderate certainty in the evidence of effects), which corresponds
to 0 fewer major bleeding events (2 fewer to 4 more) per 1000
patients. Similarly, rates of reoperation may not be meaningfully
increased (RR, 1.43; 95% CI, 0.75-2.71; moderate certainty in the
evidence of effects) given the low event rates; this corresponds to
0 fewer reoperations (0 fewer to 2 more) per 1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidenceof effects asmoderate basedon the lowest certainty
in the evidence for the critical outcomes, downgrading for imprecision.
Other EtD criteria and considerations. The panel judged the
desirable and undesirable effects as being small and trivial,
respectively, in magnitude. Cost-effectiveness was judged to
probably favor the use of DOACs. Similarly, equity, acceptability,
and feasibility each favored the use of DOACs and contributed to
the recommendation in their favor. Use of out-of-hospital pro-
phylaxis, which is routine following total hip or knee arthroplasty,
particularly favored DOACs over LMWH, given the need for
parenteral administration of the latter agent.
Conclusions and research needs for this recommendation.
The guideline panel suggests using DOACs rather than LMWH for
patients undergoing total hip or knee arthroplasty. Based on an
overall moderate certainty in the evidence of effects, the panel
judged the balance of effects to probably favor the use of
DOACs over LMWH. The ultimate judgment of a conditional
recommendation for DOACs was based on anonymous voting by
panel members without direct financial conflicts, with a majority of 5
voting for this recommendation (vs 4 in favor of a recommendation
for using either). The panel recommended a need for large clinical
trials using clinically relevant end points comparing different
DOACs. Further studies regarding the optimal timing of the
initiation of postoperative dosing of DOACs are warranted.
Question: Should 1 DOAC vs another DOAC be used for patients
undergoing total hip or knee arthroplasty?
Recommendation 11
For patients undergoing surgery, the ASH guideline panel
suggests using any of the DOACs approved for use (condi-
tional recommendation based on low certainty in the evidence
of effects ÅÅ◯◯).
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Summary of the evidence. We found no study that compared
different classes of DOACs or individual DOACs of the same class
head to head. Therefore, we used the body of evidence
comparing DOAC prophylaxis vs LMWH (see recommendation
10) as the basis for an indirect assessment of their relative
effectiveness.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/16A3927F-FB2D-C278-9FE5-D4535020FE27.
Benefits. In the absence of comparative trials of different classes
of DOACs (anti–factor IIa vs anti–factor Xa) or individual DOACs of
the same class, we tested potential differences by analyzing potential
subgroup effects. Based on the tests for interaction, we did not
demonstrate any evidence for a clinically relevant subgroup effect for
any of the potentially desirable outcomes. Based on this finding, the
panel assumed that the beneficial effects were likely similar for different
DOACs.
Harms and burden. Similarly, based on tests for interaction, we
did not find any evidence for a clinically relevant subgroup effect for
any of the potentially undesirable outcomes. Based on this finding,
the panel assumed that the undesirable effects were likely similar for
different DOACs.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
for indirectness and imprecision.
Other EtD criteria and considerations. Based on these
findings, the panel judged that the balance of effects did not favor any
particular DOAC over another. The panel also judged that issues
surrounding cost-effectiveness, equity, acceptability, and feasibility also
did not weigh in sufficiently to favor 1 DOAC over another.
Conclusions and research needs for this recommendation.
Based on overall low certainty in the evidence of effects, the panel
judged that there were no net benefits in favor of any DOAC vs
another. Given the lack of direct comparative evidence, the panel
identified an important need for high-quality head-to-head studies
comparing different DOACs for the prevention of VTEs following
total hip or knee arthroplasty.
Question: Should LMWH vs warfarin be used for patients
undergoing total hip or knee arthroplasty?
Recommendation 12
For patients undergoing total hip arthroplasty or total knee
arthroplasty, if a DOAC is not used, the ASH guideline panel
suggests using LMWH rather than warfarin (conditional rec-
ommendation based on very low certainty in the evidence of
effects Å◯◯◯).
Summary of the evidence. We identified 1 systematic review
that addressed this question.236 We identified 7 trials in this review
that fulfilled our inclusion criteria and measured outcomes relevant
to this context.39,219,237-241 Our systematic search of RCTs did not
identify any additional study that fulfilled the inclusion criteria. Three
studies were conducted with patients undergoing total hip
arthroplasty,39,239,241 3 studies were conducted with patients
undergoing total knee arthroplasty,219,237,240 and 1 study addressed
both populations.238 Five studies219,237-240 reported the effect of
LMWH compared with warfarin on mortality, 5 studies reported the
effect on the development of symptomatic PEs,39,219,237,238,240 6
studies reported on any proximal DVT,219,237-241 and 2 studies
reported on any distal DVT.237,241 All 7 studies reported the effect
on the risk of major bleeding,39,219,237-241 and 2 studies reported on
the risk of reoperation.237,241
The EtD framework is available online at https://guidelines.gradepro.org/
profile/BC1783C1-D62B-AECB-B9F7-87A9D474A834.
Benefits. LMWH may result in little or no difference in mortality
compared with warfarin (RR, 0.51; 95%CI, 0.14-1.88; low certainty
in the evidence of effects). LMWH likely does not reduce
symptomatic PEs (RR, 0.83; 0.27-2.54; moderate certainty in the
evidence of effects). LMWH may reduce symptomatic proximal
DVTs (RR, 0.61; 95% CI, 0.36-1.02; very low certainty in the
evidence of effects) and symptomatic distal DVTs (RR, 0.61;
95% CI, 0.42-0.88; low certainty in the evidence of effects).
This corresponds to 2 fewer (0-4 fewer) symptomatic proximal
DVTs and 0 fewer symptomatic distal DVTs with the use of
LMWH than with warfarin for 1000 patients treated, based on
baseline risks of 0.6% and 0.049%, respectively, from observational
data.202,203
Harms and burden. LMWH use likely results in increased
major bleeding compared with the use of warfarin (RR, 1.81;
95% CI, 1.31-2.50; moderate certainty in the evidence of
effects). This corresponded to 16 more (5-22 more) major
bleeds per 1000 patients. There was no difference with regard to
reoperation rates between those receiving LMWH or warfarin (RR,
3.09; 95% CI, 0.13-75.48; moderate certainty in the evidence of
effects), which corresponded to 0 more events per 1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the
lowest certainty in the evidence for the critical outcomes,
downgrading for study limitations and very serious imprecision.
Other EtD criteria and considerations. The panel judged
that there was possibly important uncertainty or variability in
how much people value the main outcomes. The balance
between desirable und undesirable effects probably favored
LMWH. Resources requirements of warfarin were deemed
moderate, particularly with regard to the need for, and the
complexity of, anticoagulant monitoring, but cost-effectiveness
data probably did not favor warfarin or LMWH. There probably
would be no impact on health equity; both agents appear
acceptable to stakeholders and are feasible to implement.
Conclusions and research needs for this recommendation.
The guideline panel suggests using LMWH rather than warfarin for
patients undergoing total hip arthroplasty or total knee arthroplasty.
The guideline panel determined that there was very low certainty
evidence for a net health benefit/harm from using LMWH rather
than warfarin. Based on the body of available evidence, it is likely
that warfarin reduces the risk of major bleeding based on evidence
of moderate certainty. However, it may also increase the risk of
proximal DVTs, based on very low quality evidence.
Further high-quality studies using clinically important outcomes
would be of value to improve the certainty in the recommendation.
However, given the availability of DOACs as oral agents that do
not require anticoagulant monitoring or dose adjustment, further
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clinical trials using warfarin are not regarded as a high priority at
this time.
Question: Should LMWH vs UFH be used for patients undergoing
total hip or knee arthroplasty?
Recommendation 13
For patients undergoing total hip arthroplasty or total knee
arthroplasty, if a DOAC is not used, the ASH guideline panel
suggests using LMWH rather than UFH (strong recommenda-
tion based on moderate certainty in the evidence of effects
ÅÅÅ◯).
Summary of the evidence. We identified 1 systematic review
that addressed this question.236 We identified 12 trials in this
review that fulfilled our inclusion criteria and measured outcomes
relevant to this context.242-253 Our systematic search of RCTs did
not identify any additional study that fulfilled the inclusion criteria.
Ten trials were performed on patients undergoing total hip
arthroplasty,242-244,246,247,249-253 and 2 trials were conducted on
patients undergoing total knee arthroplasty.245,248 Five trials
reported the effect of LMWH compared with UFH on
mortality,244,247,249,251,252 10 studies reported the effect on the
development of symptomatic PEs,242-245,247-249,251-253 8 studies
reported the effect on any proximal DVT,242,244-249,251 and 6 studies
reported the effect on any distal DVT.242,244-249,251 Six studies reported
the effect on the risk of major bleeding,244,245,249-251,253 and 2 studies
reported the effect on the risk of reoperation.247,248
The EtD framework is available online at https://guidelines.gradepro.org/
profile/06FDBFB0-4D4E-E0D0-AEAD-C8B371DFA939.
Benefits. LMWH results in little or no difference in mortality
compared with UFH (RR, 0.26; 95% CI, 0.03-2.36; high certainty
in the evidence of effects), which corresponded to 3 fewer (4
fewer to 5 more) deaths per 1000 patients. LMWH probably
reduces the risk of symptomatic PEs slightly (RR, 0.37; 95% CI,
0.19-0.71; moderate certainty in the evidence of effects). This
corresponds to 4 fewer (2-5 fewer) symptomatic PEs per 1000
patients, based on a baseline risk of 0.6% from observational
data.202,203 LMWH also likely reduces the risk of symptomatic
proximal DVTs (RR, 0.48; 95% CI, 0.34-0.69; moderate certainty
in the evidence of effects), corresponding to 3 fewer (2-4 fewer)
per 1000 patients, based on a baseline risk of 0.6% from
observational data.202,203 LMWH appears to result in little or no
difference in symptomatic distal DVTs (RR, 1.18; 95% CI, 0.81-
1.72; low certainty in the evidence of effects), with very small
corresponding absolute effect size estimates based on a baseline
risk of 0.049% from observational data.202,203
Harms and burden. LMWH likely results in a small decrease in
the risk of major bleeding (RR, 0.55; 95% CI, 0.27-1.13; moderate
certainty in the evidence of effects); this corresponds to 19 fewer
(30 fewer to 5 more) major bleeds per 1000 patients. We were
unable to estimate an effect on the risk of reoperation given that the
included studies reported no events for this outcome.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as moderate based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
imprecision.
Other EtD criteria and considerations. The panel deter-
mined that there was probably important uncertainty or variabil-
ity in how much affected individuals value the main outcomes.
Cost-effectiveness likely differs by country but probably favors
LMWH. The panel assessed that this recommendation probably
would have no impact on health equity and would be acceptable
to stakeholders. LMWH is already widely used, and the panel
had no concern about the feasibility of implementation.
Conclusions and research needs for this recommendation.
The guideline panel recommends LMWH rather than UFH for patients
undergoing total hip arthroplasty or total knee arthroplasty.
The guideline panel determined that there is moderate certainty
evidence for a net health benefit/harm from using LMWH over UFH.
Future large studies using clinically relevant end points would help
to better inform this recommendation, although this research
question would not be regarded as high priority.
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients undergoing hip fracture
repair?
Recommendation 14
For patients undergoing hip fracture repair, the ASH guideline
panel suggests using pharmacological prophylaxis over no
pharmacological prophylaxis (conditional recommendation
based on very low certainty in the evidence of effects Å◯◯◯).
Summary of the evidence. We identified 1 systematic
review254 that addressed, in part, this question. We identified
5 studies in this review that fulfilled our inclusion criteria and
measured outcomes relevant to this context.255-259 Our system-
atic search of RCTs identified 7 additional studies that fulfilled
the inclusion criteria.260-266 Nine studies reported the effect of
pharmacological prophylaxis compared with no intervention on
risk of mortality.255,256,258,259,261-265 Nine studies reported the
effect on development of any PEs,255-259,261,264-266 and 5
studies reported the effect of any proximal DVT and any distal
DVT.257,260,261,263,265 Eleven studies reported the effect of pharma-
cological prophylaxis compared with no intervention on risk of major
bleeding,255,256,258-266 and 3 studies reported the effect on risk of
reoperation.258,261,266
We tested potential differences in the effects with ASA and anti-
coagulant prophylaxis and performed a subgroup analysis. The
analysis indicated no subgroup effect with regard to desirable and
undesirable effects comparing ASA with anticoagulant prophylaxis.
As a result, in this analysis, studies with ASA are pooled with those
of anticoagulant prophylaxis compared with no pharmacological
prophylaxis.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/A10CDC06-B411-D572-959A-A8405E1373A1.
Benefits. Pharmacological prophylaxis appears to result in little
or no difference in mortality (RR, 0.95; 95% CI, 0.84-1.07; very low
certainty in the evidence of effects), although we are very uncertain
about this finding. This would correspond to 4 fewer deaths
(11 fewer to 5 more) per 1000 patients based on a baseline risk of
7.1% from the control group event rate in the meta-analysis.
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Pharmacological prophylaxis may reduce symptomatic PEs (RR,
0.49; 95% CI, 0.33-0.72; very low certainty in the evidence of
effects), but we are very uncertain of this finding. This corresponds
to 6 fewer (3-7 fewer) events per 1000 patients based on a baseline
risk of 1.1% from the control group event rate in the meta-analysis.
Based on lower baseline risk of 0.3% from observational data,267
this would correspond to 2 fewer (1-2 fewer) symptomatic PEs per
1000 patients. Pharmacological prophylaxis may reduce symptom-
atic proximal DVTs (RR, 0.51; 95% CI, 0.38-0.69; very low certainty
in the evidence of effects), but we are very uncertain of this finding.
In a moderate-risk population with a baseline risk of 2.5%,267 this
corresponds to 12 fewer (8-16 fewer) per 1000 patients. Pharmaco-
logical prophylaxis likely has little or no effect on symptomatic distal
DVTs (RR, 0.85; 95%CI, 0.56-1.29; very low certainty in the evidence
of effects), but once again we are very uncertain of this finding.
Harms and burden. Pharmacological prophylaxis may increase
major bleeding (RR, 1.24; 95% CI, 1.12-1.37; low certainty in the
evidence of effects). Depending on baseline risk, this corresponds
to 1 more (1-2 more) major bleed per 1000 patients in a lower-risk
population (baseline risk of 0.5% from observational data)267 or
as many as 20 more (10-31 more) per 1000 patients in a higher-
risk population (baseline risk of 8% from the control group event
rate in the meta-analysis). Pharmacological prophylaxis appears to
have little or no effect on the need for reoperation (RR, 1.05; 95%
CI, 0.82-1.35; very low certainty in the evidence of effects);
however, we are very uncertain of this finding.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, indirectness, and very serious imprecision.
Other EtD criteria and considerations. The panel judged the
magnitude of the desirable effects as moderate in size and the
undesirable effects as small in size. There was possibly important
uncertainty or variability about how patients may value these outcomes.
There would probably be no impact on equity, and the panel foresaw
no issues with regard to acceptability and feasibility of using
pharmacological prophylaxis in this patient population.
Conclusions and research needs for this recommendation.
Although the overall certainty in the evidence of effects was very
low, the panel judged that the balance of effects probably favored
the use of pharmacological prophylaxis for VTE prophylaxis following
hip fracture repair. Given the overall very low certainty in the evidence,
the panel indicated that there remains an important need for large
high-quality RCTs using clinically important end points to determine
the optimal role of ASA or anticoagulant pharmacological pro-
phylaxis in this patient population. However, higher priority would be
comparative studies of different antithrombotic regimens for the
prevention of VTEs in these patients requiring repair of hip fracture.
Question: Should LMWH prophylaxis vs UFH prophylaxis be used
for patients undergoing hip fracture repair?
Recommendation 15
For patients undergoing hip fracture repair, the ASH guideline
panel suggests using LMWH or UFH (conditional recommenda-
tion based on very low certainty in the evidence of effectsÅ◯◯◯).
Summary of the evidence. We identified 1 systematic re-
view254 that addressed this question. We identified 3 studies in this
review that fulfilled our inclusion criteria and measured outcomes
relevant to this context.268-270 Our update of the systematic review
did not identify any additional study that fulfilled the inclusion
criteria. Two studies reported the effect of LMWH prophylaxis
compared with UFH prophylaxis on risk of mortality, as well as any
proximal and distal DVTs,268,269 and 3 studies reported the effect
on any PEs and major bleeding.268-270 No information on
reoperation rates was available in any of the included studies.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/80C377E5-E3C0-36CD-B646-C2532AB4D4B9.
Benefits. LMWH appears to result in little or no difference in
mortality compared with UFH prophylaxis following hip fracture
repair (RR, 0.47; 95% CI, 0.10-2.12; very low certainty in the
evidence of effects), although we are very uncertain about the
effect. Assuming a baseline risk of 7.4% for UFH-treated patients,
this would correspond to 39 fewer (66 fewer to 88 more) deaths per
1000 patients. We are very uncertain about the effect of LMWH on
symptomatic PEs (RR, 2.13; 95%CI, 0.06-81.3; very low certainty in the
evidence of effect). LMWH may result in a small, possibly unimportant,
increase in symptomatic proximal DVTs (RR, 2.24; 95% CI, 0.92-5.43;
low certainty in the evidence of effect) corresponding to 31 more (2
fewer to 111 more) per 1000 patients based on a baseline risk of
2.5% from observational data.267 LMWH appears to result in
little or no difference in symptomatic distal DVTs (RR, 0.66; 95%
CI, 0.21-2.17; very low certainty in the evidence of effects).
Harms and burden. LMWH appears to result in little or no
difference in major bleeding compared with UFH after hip fracture
surgery (RR, 0.85; 95% CI, 0.19-3.79; very low certainty in the
evidence of effects). This corresponds to 9 fewer (50 fewer to
173 more) major bleeds per 1000 moderate-risk patients with a
baseline risk of 6.2% based on a lower baseline risk of 0.5%
from observational data267; the corresponding absolute risk
reduction would be 1 fewer (4 fewer to 14 more) per 1000
patients. No comparative information is available regarding the risks
of reoperation following hip fracture with the use of LMWH or UFH.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, indirectness, and very serious imprecision.
Other EtD criteria and considerations. The panel determined
that there was possibly important uncertainty or variability in how
much affected individuals valued the main outcomes. They further
judged that the balance between desirable and undesirable effects
did not favor LMWH or UFH following hip fracture repair. The panel
recognized the very low certainty in comparative evidence, which
was based on three small RCTs that did not report symptomatic DVT
outcomes. The panel recognized that the comparative resources
associated with LMWH and UFH prophylaxis were probably
negligible. Cost-effectiveness was considered to favor LMWH
based upon results of a single study.271 Using LMWH or UFH
would probably not impact health equity, and either drug was
deemed to be probably acceptable to stakeholders and feasible to
implement.
Conclusions and research needs for this recommendation.
Taking into consideration the very low certainty in the evidence,
the panel judged that LMWH or UFH prophylaxis could be
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recommended following hip fracture repair. Large RCTs using
clinically important outcomes are needed to better define the
relative benefits and risks of LMWH compared with UFH following
hip fracture surgery.
Major general surgery
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients undergoing major general
surgery?
Recommendation 16
For patients undergoing major general surgery, the ASH guideline
panel suggests using pharmacological prophylaxis over no phar-
macological prophylaxis (conditional recommendation based
on low certainty in the evidence of effects ÅÅ◯◯).
Summary of the evidence. We identified a systematic review
of RCTs272 addressing this research question. We identified 3
studies273-275 in this review that fulfilled our inclusion criteria
and measured outcomes relevant to this context. Our
systematic search for RCTs identified 3249,122,125,131,274,276-302
additional studies that fulfilled the inclusion criteria, in-
cluding patients undergoing major general surgery. Sixteen
studies122,125,274-278,284,285,291,293,296,297,299,300,302 reported
the effect of pharmacological prophylaxis vs no pharma-
cological prophylaxis on the risk of mortality, and 11
studies125,273,276-279,285,286,289,293,295 reported the effect on
the development of symptomatic PEs. Six studies49,125,278,285,287,290
reported the effect on development of screening-detected proximal
DVTs, and 6 studies124,277,283,284,286,289 reported the effect on
development of screening-detected distal DVTs.
Twelve studies125,273-276,282,285,287,293,295,297,298 reported the effect
of pharmacological prophylaxis vs no pharmacological prophylaxis on
risk of major bleeding, and 3 studies275,282,295 reported the effect on
risk of reoperation.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/3B5A5678-B1D9-4D60-8E1F-F3AD700132F8.
Benefits. Pharmacological prophylaxis compared with no
pharmacological prophylaxis probably reduces mortality (RR,
0.76; 95% CI, 0.61-0.93; moderate certainty in the evidence of
effects). This finding corresponds to 4 fewer deaths (1-7 fewer) per
1000 patients undergoing major general surgery. Pharmacological
prophylaxis probably also reduces symptomatic PEs (RR, 0.45; 95%
CI, 0.23-0.88; moderate certainty in the evidence of effects). This
corresponds to 4 fewer (1-6 fewer) pulmonary embolic events per
1000 patients undergoing major general surgery. Pharmacological
prophylaxis may also reduce symptomatic proximal DVTs (RR, 0.38;
95% CI, 0.14-1.00; very low certainty in the evidence of effects), but
we are very uncertain of this finding. This corresponds to 10 fewer (0-
14 fewer) symptomatic proximal DVTs per 1000 patients based on a
baseline risk of 1.6% from observational data.73 It may reduce
symptomatic distal DVTs (RR, 0.57; 95%CI, 0.36-0.90; low certainty
in the evidence of effects), which corresponds to 1 fewer (0-1 fewer)
symptomatic distal DVT per 1000 patients undergoing major general
surgery based on a baseline risk of 1.6% from observational data.73
Harms and burden. Pharmacological prophylaxis probably
increases major bleeding (RR, 1.37; 95%CI, 0.89-2.13; moderate
certainty in the evidence of effects). This corresponds to 10 more (3
fewer to 29 more) major bleeding events per 1000 patients
undergoing major general surgery. Pharmacological prophylaxis
results in little or no difference in reoperation (RR, 0.75; 95% CI,
0.21-2.77; low certainty in the evidence of effects).
Certainty in the evidence of effects. The overall certainty of
the estimates of effects was based on the low certainty outcomes
and was not based on the lowest certainty of evidence for the
critical outcomes. In this case, the recommendation was sufficiently
supported by the favorable impact on desirable effects for which
there was higher quality evidence.
Other EtD criteria and considerations. The panel judged the
desirable effects to be of moderate magnitude and the undesirable
effects to be of small magnitude. They assumed that there was
possibly important uncertainty or variability in patients’ values.
Pharmacological prophylaxis probably would incur moderate
additional costs but was judged to be probably cost-effective.
Pharmacological prophylaxis would probably have no impact on
equity, was probably acceptable, and was likely feasible.
Conclusions and research needs for this recommendation.
The panel judged that the overall balance of effects favored
pharmacological prophylaxis over no pharmacological prophylaxis
for patients undergoing major general surgery based on low
certainty in the evidence of effects. Further high-quality comparative
studies, using appropriate clinical outcomes, would be of value to
add more certainty to these recommendations. However, such
studies would not be considered as high priority by the panel.
Question: Should LMWH prophylaxis vs UFH prophylaxis be used
for patients undergoing major general surgery?
Recommendation 17
For patients undergoing major general surgery, the ASH guideline
panel suggests using LMWH or UFH (conditional recommenda-
tion based on very low certainty in the evidence of effectsÅ◯◯◯).
Summary of the evidence. We identified 2 systematic
reviews of RCTs272,303 addressing this research question. We
identified 40 studies304-343 in these reviews that fulfilled our
inclusion criteria and measured outcomes relevant to this context.
Our systematic search for RCTs identified 6 additional
studies295,344-348 that fulfilled the inclusion criteria. Thirty
studies reported the effect of LMWH vs UFH on risk of
mortality.305,307,308,310-312,314,317-319,321,322,325-327,329-339,341,342,346,347
Thirty-one studies reported the effect of LMWH vs UFH on development
of symptomatic PEs,295,305-306,310-312,314-319,321,322,324,326-335,337,339,344-346
5 studies reported the effect on symptomatic proximal
DVTs,306,316,326,334,336 and 7 reported the effect on symptom-
atic distal DVTs.306,316,326,329,334,336,341 Thirty-four studies
reported the effect of LMWH vs UFH on risk of major
bleeding,295,305-307,311,313,315-319,321-339,341,344-346 and 16 studies reported
the effect on risk of reoperation.305,307,309,317,319,322,323,326,329,330,333-337,341
The EtD framework is available online at https://guidelines.gradepro.org/
profile/EF7ADEA0-49F1-7E89-A0DB-DE7A9E854A2B.
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Benefits. Prophylaxis with LMWH vs UFH probably does not
reduce mortality following major general surgery (RR, 1.03; 95%
CI, 0.89-1.18; moderate certainty in the evidence of effects).
We are very uncertain about the effect of LMWH on
symptomatic PEs compared with that of UFH (RR, 0.83; 95%
CI, 0.58-1.19; very low certainty in the evidence of effects), which
corresponds to 1 fewer (3 fewer to 2 more) symptomatic PE per 1000
patients undergoing major general surgery based on a baseline
risk of 0.8% from observational data.73 It also appears to result in little or
no difference in symptomatic proximal DVTs (RR, 1.01; 95% CI, 0.20-
5.00; very low certainty in the evidence of effects) or a reduction in
symptomatic distal DVTs (RR, 1.01; 95%CI, 0.30-3.44; very low certainty
in the evidence of effects).We are very uncertain about the last 2 findings.
Harms and burden. Prophylaxis with LMWH vs UFH probably
does not affect major bleeding (RR, 0.97; 95% CI, 0.78-1.20;
moderate certainty in the evidence of effects). This corresponds to
0 fewer (3 fewer to 3 more) major bleeding events per 1000
patients undergoing major general surgery. LMWH probably results
in little or no difference in reoperations (RR, 0.79; 95% CI, 0.57-
1.08; moderate certainty in the evidence of effects), which
corresponds to 3 fewer (6 fewer to 1 more) reoperations per
1000 patients undergoing major general surgery.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
for study limitations and very serious inconsistency.
Other EtD criteria and considerations. There was possibly
important uncertainty or variability in how patients valued the
outcomes. Potential costs and savings were deemed of
negligible relevance, assuming only in-hospital short-term pro-
phylaxis. There was probably no impact on equity, because both
LMWH and UFH were thought to be acceptable and feasible to
implement. If extended prophylaxis beyond hospital discharge is
planned, LMWH may be preferable given its once-daily dosing. The
panel thought that both treatment options are already widely used
and there should be few issues with implementation.
Conclusions and research needs for this recommendation.
The guideline panel judged that the net benefit did not favor LMWH
or UFH prophylaxis for patients undergoing major general surgery.
Based on a very low overall certainty in the evidence, the panel
determined that the balance of effects did not favor LMWH or UFH.
In light of the very low certainty in the evidence, further high-quality
comparative studies, using appropriate clinical outcomes, would be
of value to add more certainty to this recommendation. However, such
comparative studies are not regarded as high priority at this time.
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients undergoing laparoscopic
cholecystectomy?
Recommendation 18
For patients undergoing laparoscopic cholecystectomy, the
ASH guideline panel suggests against using pharmacological
prophylaxis (conditional recommendation based on very low cer-
tainty in the evidence of effects Å◯◯◯). Remark: Patients with
other risk factors for VTEs (eg, history of VTE, thrombophilia, or
malignancy) may benefit from pharmacological prophylaxis.
Summary of the evidence. We identified 1 systematic review of
RCTs addressing this research question.30 We identified 2
studies118,349 in that review that fulfilled our inclusion criteria and
measured outcomes relevant to this context. Because of the relative
paucity of studies on patients undergoing laparoscopic cholecys-
tectomy, data across major general, major gynecological, and
major urological procedures were pooled, and laparoscopic
cholecystectomy-specific baseline risk estimates were ap-
plied.350 Five studies66,294,301,351,352 were conducted on
patients undergoing major gynecological surgery. Thirty-
one49,122,125,131,275-279,281-293,295-300,302 studies were con-
ducted on patients undergoing major general surgery. Two
studies118,349 were conducted on patients undergoing laparo-
scopic cholecystectomy. Six studies38,280,353-356 were con-
ducted on patients undergoing urological surgery. Eighteen
studies122,125,274-278,284,285,291,293,296,297,299,300,302,353,354 reported the
effect of pharmacological prophylaxis vs no pharmacological prophylaxis
on risk of mortality, 16 studies38,118,125,273,276-279,285,286,289,293,295,354-356
reported the effect on risk of symptomatic PEs, 6 studies49,125,278,285,287,290
reported the effect on risk of screening-detected proximal
DVTs, and 7 studies66,125,278,284,285,287,290 reported the
effect on risk of screening-detected distal DVTs. Fifteen
studies118,125,273-275,277,282,285,287,293,295,297,298,349,354 reported
the effect of pharmacological prophylaxis vs no pharmacological
prophylaxis on risk of major bleeding, and 6 studies38,118,275,282,295,354
reported the effect on risk of reoperation.
The EtD framework is available online at https://guidelines.grade-
pro.org/profile/E753AE97-D04A-D35F-ABE1-F9CAB9461DD1.
Benefits. Pharmacological prophylaxis probably results in a small
unimportant reduction in overall mortality (RR, 0.75; 95% CI, 0.61-
0.93; low certainty in the evidence of effects). This corresponds
to 2 fewer (0-2 fewer) deaths per 1000 patients based on a
baseline risk of 0.6% from observational data.357 It may not reduce
symptomatic PEs following laparoscopic cholecystectomy (RR,
0.48; 95% CI, 0.26-0.88; very low in the evidence of effects), but
we are very uncertain of this finding. Given the very low baseline risk
of VTE events in this specific patient population,350 this would be
expected to result in 0 fewer (0 fewer to 0 more) symptomatic
PEs per 1000 patients. Similarly, pharmacological prophylaxis
may not reduce symptomatic proximal DVTs (RR, 0.38; 95% CI,
0.14-1.00; very low certainty in the evidence of effects) or
symptomatic distal DVTs (RR, 0.52; 95% CI, 0.31-0.87; very low
certainty in the evidence of effects). Again, given the very low
baseline risks, this would correspond to 0 fewer (0 fewer to
0 more) events per 1000 patients for both outcomes. We are
very uncertain about the effects on symptomatic proximal DVTs
and symptomatic distal DVTs.
Harms and burden. Pharmacological prophylaxis may result in a
small increase in major bleeding (RR, 1.24; 95% CI, 0.87-1.77; low
certainty in the evidence of effects). This would be expected to
result in 6 more (3 fewer to 20 more) major bleeds per 1000
patients. We are very uncertain whether pharmacological pro-
phylaxis results in little or no difference in reoperation (RR, 0.93;
95% CI, 0.35-2.50; very low certainty in the evidence of effects);
this corresponds to 1 fewer (8 fewer to 18 more) reoperation per
1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
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certainty in the evidence for the critical outcomes, downgrading for
study limitations, indirectness, and imprecision.
Other EtD criteria and considerations. The panel based this
recommendation on the trivial incremental benefits and the small
increased risk of major bleeding associated with pharmacological
prophylaxis. The panel judged that the potential benefits of pharmaco-
logical prophylaxis were outweighed by the small increased risk of major
bleeding in average-risk patients undergoing laparoscopic cholecys-
tectomy. This relates to the very low baseline risk of VTE for patients
undergoing laparoscopic cholecystectomy. The panel discounted the
mortality difference observed in this analysis as unlikely to relate to
pharmacological prophylaxis, given the very low baseline risk of VTE.
Patientswith other risk factors for VTE (eg, history of VTE, thrombophilia,
or malignancy) may benefit from pharmacological prophylaxis.
Conclusions and research needs for this recommendation.
The guideline panel determined that potential undesirable effects
of pharmacological prophylaxis, in particular major bleeding, out-
weighed its potential benefit for patients undergoing laparoscopic
cholecystectomy. The panel acknowledges that the overall certainty
in the evidence was low, in particular as a result of indirectness, with
most of the trial data included in the analysis involving patients
undergoing major surgical procedures. Further research into
pharmacological prophylaxis following laparoscopic cholecystec-
tomy was not regarded as high priority given the low baseline
incidence of VTE complications in this patient population.
Major neurosurgical procedures
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients undergoing major
neurosurgical procedures?
Recommendation 19
For patients undergoing major neurosurgical procedures, the
ASH guideline panel suggests against using pharmacological
prophylaxis (conditional recommendation based on very low
certainty in the evidence of effectsÅ◯◯◯). Remarks: Patients
undergoing major neurosurgical procedures are expected to
receive prophylaxis with mechanical methods. Pharmacological
prophylaxis may be warranted in a higher-risk subgroup of pa-
tients, such as those experiencing prolonged immobility fol-
lowing surgery. In addition, pharmacological prophylaxis could
be considered for patients undergoing major neurosurgical
procedures that carried a lower risk for major bleeding and in
those patients with persistent mobility restrictions after the
bleeding risk declines following surgery.
Summary of the evidence. We identified 1 systematic re-
view358 that addressed this question. We identified 6 studies in this
review that fulfilled our inclusion criteria and measured outcomes
relevant to this context.68,123,128,359-361 Our update of the
systematic review identified 1 additional study that fulfilled the
inclusion criteria.135 We additionally searched for and identified 3
nonrandomized studies that informed this question.362-364 All
studies included patients undergoing neurosurgical procedures.
Five studies assessed the effect of LMWH,68,128,130,135,362 4
studies assessed the effect of UFH,359,361-363 1 study assessed
the effect of warfarin,124 and 1 study assessed the effect of
heparin-dihydroergotamine.360 Additionally, across the 10 studies,
mechanical prophylaxis was used as a cointervention in 6 of the
randomized studies68,123,128,130,135,359 and in all 3 of the non-
randomized studies.361-363 Supplement 6 presents the character-
istics of all included studies.
Five RCTs68,104,128,130,359,362 and 2 nonrandomized studies361,363
reported the effect of any pharmacological thromboprophylaxis vs
no pharmacological intervention on mortality, 3 RCTs123,128,360 and
2 nonrandomized studies reported on development of PEs,361,363 2
RCTs reported on screening-detected proximal DVTs,128,130 and 1
study reported on development of screening-detected distal
DVTs.128 Seven RCTs68,123,128,130,135,359,360 and 3 nonrandom-
ized studies361-363 reported risk of major bleeding, and 2 RCTs
reported on risk of reoperation.135,359
The EtD framework is available online at https://guidelines.grade-
pro.org/profile/C5A1B92D-0E70-50BA-847C-0497617938F5.
Benefits. Pharmacological prophylaxis does not appear to
reduce mortality (RR, 1.27; 95% CI, 0.57-2.69; low certainty in
the evidence of effects) when considering the body of evidence
from RCTs, in which we have more confidence than the non-
randomized data. This corresponds to 9 more deaths (15 fewer to 65
more) per 1000 patients. Based on RCT evidence, pharmacological
prophylaxis may result in little or no difference in symptomatic PEs
(RR, 0.84; 95% CI, 0.03-27.42; very low certainty in the evidence of
effects), but we are very uncertain of this finding. This corresponds to
0 fewer events (2 fewer to 53 more) per 1000 patients based on a
baseline risk of 0.2% from observational data.364 The absolute effect
size is similarly small when considering the body of evidence from
nonrandomized trials. Pharmacological prophylaxis may result in a
small, possibly unimportant, effect on symptomatic proximal DVTs (RR,
0.50; 95% CI, 0.30 to 0.84; low certainty in the evidence of effects)
and symptomatic distal DVTs (RR, 0.60; 95% CI, 0.33-1.08; very
low certainty in the evidence of effects). This would correspond
to 6 fewer (2-8 fewer) symptomatic proximal DVTs and 0 fewer
(0-1 fewer) symptomatic distal DVTs per 1000 patients un-
dergoing major neurosurgical procedures, based on baseline risks
from observational data of 1.2% and 0.1%, respectively.364
Harms and burden. From RCTs, pharmacological prophylaxis
may increase major bleeding (RR, 1.57; 95% CI, 0.70-3.50; low
certainty in the evidence of effects), corresponding to 10 more (5
fewer to 43 more) events per 1000 patients undergoing major
neurosurgical procedures. We are very uncertain of the effect of
pharmacological prophylaxis on reoperation (RR, 0.43; 95% CI,
0.06-2.84; very low certainty in the evidence of effects), which
would correspond to 18 fewer (29 fewer to 57 more)
reoperations per 1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations and very serious imprecision.
Other EtD criteria and considerations. The panel noted that
observed RR ratios from observational studies tended to view
pharmacological prophylaxis more favorably than RCTs. The panel
based its recommendation on RR ratios from meta-analysis of RCTs
rather than observational studies, given the greater risk of bias with
the latter studies. The panel noted that the small benefit of
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pharmacological prophylaxis for the prevention of DVT was based
upon randomized controlled studies using screening venography to
detect rates of asymptomatic DVTs. The panel rated the harms of
major bleeding associated with pharmacological prophylaxis as
moderate because of the potential for greater morbidity associated
with surgical site bleeding following these procedures. The panel
recognized that patients undergoing major neurosurgical proce-
dures would routinely receive prophylaxis with mechanical
methods. The panel acknowledged that pharmacological pro-
phylaxis might still be warranted in a higher-risk subgroup of
patients, such as those experiencing prolonged immobility
following surgery. In addition, the panel acknowledged that
pharmacological prophylaxis could be considered for patients
undergoing neurosurgical procedures that carried a lower risk for
major bleeding. It may also be considered for patients with
persistent mobility restrictions after the bleeding risk subsides
following surgery.
Conclusions and research needs for this recommendation.
The panel judged, based on the available very low certainty evidence,
that the expected net benefit favored no prophylaxis following major
neurosurgical procures, because the potential small benefit of reducing
VTE events was outweighed by the potential moderate increased risk
of major bleeding. The panel also recognized that mechanical
methods of thromboprophylaxis are commonly used in this patient
population. There is a great need for the performance of large
RCTs evaluating pharmacological prophylaxis following major
neurosurgical procedures, and using clinically important end points,
to add certainty to this recommendation. The panel acknowledges
that the current recommendation may not reflect standard practice in
some centers.
Question: If pharmacological prophylaxis is indicated, should
LMWH vs UFH be used for patients undergoing major neurosur-
gical procedures?
Recommendation 20
For the subset of patients undergoing major neurosurgical
procedures for whom pharmacological prophylaxis is used, the
ASH guideline panel suggests using LMWH over UFH (con-
ditional recommendation based on very low certainty in the
evidence of effects Å◯◯◯).
Summary of the evidence. We identified 1 systematic re-
view358 that addressed this question. We identified 4 studies in this
review that fulfilled our inclusion criteria and measured outcomes
relevant to this context.348,365-367 Our update of the systematic
review identified 1 additional study that fulfilled the inclusion
criteria.368 All studies included patients undergoing neurosurgical
procedures. Five studies reported the effect of LMWH compared
with that of UFH on development of mortality,348,365-368 2 studies
reported on the development of PEs,365,366 1 study reported on the
development of screening-detected proximal DVTs,348 and 1 study
reported on screening-detected distal DVTs.366 Four studies
reported risk of major bleeding348,365-367 and 1 study reported
on risk of reoperation.366
All participants wore compression stockings, with the exception of
1 study in which their use was not reported.368
The EtD framework is available online at https://guidelines.gradepro.org/
profile/E9D1EF22-EEC9-560E-A0CC-9FD435188BBE.
Benefits. Pharmacological prophylaxis with LMWH may result in
little to no difference in mortality compared with UFH (RR, 0.34;
95% CI, 0.04-3.21; low certainty in the evidence of effects)
following major neurosurgical procedures; this corresponds to 3
fewer (5 fewer to 11 more) deaths per 1000 patients. LMWH may
result in little or no difference in symptomatic PEs (RR, 0.20; 95%
CI, 0.01-4.03; low certainty in the evidence of effects) compared
with UFH following major neurosurgical procedures. Based on a
baseline risk of 0.2% from observational data,364 this corresponds
to 2 fewer (2 fewer to 6 more) symptomatic PEs in a cohort of 1000
patients following major neurosurgical procedures. We are un-
certain whether LMWH affects proximal DVTs (RR, 1.00; 95% CI,
0.14-6.91; very low certainty in the evidence of effects). Similarly,
the impact of LMWH on symptomatic distal DVTs is very uncertain
(RR, 0.33; 95% CI, 0.01-7.93; very low certainty in the evidence of
effects). In absolute terms, this corresponds to 1 fewer (1 fewer to 7
more) symptomatic distal DVT per 1000 patients, based on a
baseline risk of 0.2% from observational data.364
Harms and burden. LMWH may result in little or no difference
in major bleeding (RR, 0.76; 95% CI, 0.20-2.95; low certainty in the
evidence of effects) compared with UFH, which corresponds
to 5 fewer (18 fewer to 43 more) major bleeding events per
1000 patients. We were unable to assess the effect on
reoperations.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations and very serious imprecision.
Other EtD criteria and considerations. In formulating this
recommendation, the panel formally acknowledges its prior
conditional recommendation against pharmacological prophy-
laxis (Recommendation 19) for patients undergoing neurosurgi-
cal procedures. Nevertheless, if pharmacological prophylaxis is
considered, the panel judged the desirable effects of LMWH
over UFH as small and the undesirable effects as trivial.
Considering the very low certainty in the evidence, and possibly
important uncertainty about or variability in how much people
value the main outcomes, the balance of effects favored LMWH.
Equity, acceptability, and feasibility were not considered major
factors.
Conclusions and research needs for this recommendation.
In the subset of high-risk patients following major neurosurgi-
cal procedures for whom pharmacological prophylaxis is being
considered, the ASH guideline panel judged the net benefit to
favor LMWH over UFH. The panel recognizes this as being
based upon very low certainty in the evidence.
The research priorities following major neurosurgical procedures
are to better establish the benefits and risks of any pharmacological
prophylaxis compared with no pharmacological prophylaxis. For
patients considered at very high risk of postoperative VTE and at low
bleeding risk, high-quality comparative studies of LMWH vs UFH using
clinically important outcome measures would be of value.
Urological procedures. Question: Should pharmacological
prophylaxis vs no pharmacological prophylaxis be used for patients
undergoing TURP?
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Recommendation 21
For patients undergoing TURP, the ASH guideline panel sug-
gests against using pharmacological prophylaxis (conditional
recommendation based on very low certainty in the evidence of
effects Å◯◯◯). Remark: Patients with other risk factors for
VTE (eg, history of VTE, thrombophilia, or malignancy) may
benefit from pharmacological prophylaxis.
Summary of the evidence. We did not identify any systematic
reviews of RCTs addressing this research question. Because of
the paucity of studies related to TURP, data across all major
general, urological, and gynecological surgical procedures were
pooled, and TURP-specific baseline risk estimates were applied,
where available. The evidence base to inform the relative
effectiveness of pharmacological prophylaxis vs no pharmacolog-
ical prophylaxis was comparable to that used to inform this
question for patients undergoing laparoscopic cholecystectomy
(see Recommendation 18). To determine the desirable and
undesirable effects of prophylaxis in absolute terms, the
baseline risks specific for TURP outcomes were drawn from a
systematic review by Tikkinen et al369 and from observational
studies.370-372
The EtD framework is available online at https://guidelines.gradepro.org/
profile/05201A35-BCDA-9EFA-98CB-892C0AB72944.
Benefits. Pharmacological prophylaxis may not reduce overall
mortality compared with no pharmacological prophylaxis (RR, 0.75;
95% CI, 0.61 to 0.93; low certainty in the evidence of effects). This
corresponds to 1 fewer (0-1 fewer) death per 1000 patients
undergoing TURP. Pharmacological prophylaxis may not reduce
symptomatic PEs (RR, 0.48; 95% CI, 0.26 to 0.88; low certainty in
the evidence of effects), which corresponds to 0 fewer events in
lower-risk patients and 0 fewer (0-1 fewer) events in higher-risk
patients undergoing TURP. We are very uncertain of its effect on
symptomatic proximal DVTs (RR, 0.38; 95% CI, 0.14-1.00; very
low certainty in the evidence of effects), which would
correspond to 1 fewer (0-1 fewer) symptomatic event in 1000
lower-risk patients or 3 fewer (0-5 fewer) events per 1000 higher-risk
patients. We are very uncertain about its effect on symptomatic distal
DVTs (RR, 0.52; 95% CI, 0.31-0.87; very low certainty in the
evidence of effects). Based upon the very low baseline risk for
patients undergoing TURP, this would correspond to 0 fewer
symptomatic events per 1000 higher-risk patients.
Harms and burden. The risk of major bleeding is probably
slightly increased (RR, 1.24; 95%CI, 0.87-1.77; moderate certainty
in the evidence of effects) with the use of pharmacological
prophylaxis. This corresponds to 6 more (3 fewer to 20 more)
major bleeding events per 1000 patients. We are very uncertain
about reoperations (RR, 0.93; 95% CI, 0.35-2.50; very low
certainty in the evidence of effects) related to pharmacological
prophylaxis.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the
lowest certainty in the evidence for the critical outcomes, down-
grading for study limitations, indirectness, and imprecision.
Other EtD criteria and considerations. The panel judged the
desirable effects of pharmacological prophylaxis for patients
undergoing TURP as trivial and the undesirable effects as small in
magnitude. It further judged that there was possibly important
uncertainty or variability in how much people value the main
outcomes. Based primarily on the very low baseline risk of VTE
following TURP, the panel judged that the balance of effects
ultimately favored not using pharmacological prophylaxis. Pharma-
cological prophylaxis would also incur moderate costs and not be
cost-effective.
Conclusions and research needs for this recommendation.
The guideline panel suggests against pharmacological prophylaxis
for patients undergoing TURP. Based on overall very low certainty
in the evidence, the panel judged that the desirable effects of
pharmacological prophylaxis were outweighed by the undesirable
effects, specifically the increased risk of bleeding in this setting.
Given the very low baseline risks of VTE following this procedure
and the increasing use of alternative modalities to treat lower
urinary tract symptoms attributed to benign prostatic hyperplasia,373
further RCTs conducted on patients undergoing TURP do not
appear to be a major priority.
Question: If pharmacological prophylaxis is indicated, should
LMWH vs UFH be used for patients undergoing TURP?
Recommendation 22
For the subset of patients undergoing TURP for whom phar-
macological prophylaxis is used, the ASH guideline panel sug-
gests using LMWH or UFH (conditional recommendation based
on very low certainty in the evidence of effects Å◯◯◯).
Summary of the evidence. We did not identify any system-
atic reviews of RCTs addressing this research question.
Because of the paucity of studies related to TURP,
data across all major general, urological, and gynecologi-
cal surgical procedures were pooled. Thirty-one stud-
ies reported the effect of LMWH vs UFH on risk of
mortality,305,307,308,310-312,314,317-319,321,322,325-327,329-339,341,342,346,347,374
and 36 studies reported on development of symptomatic
PEs.295,305-307,310-312,314-319,321,322,324,326-335,337,339,344-346,374-378 Six
studies reported the effect of LMWH vs UFH on development of
symptomatic proximal DVTs,306,316,326,334,336,375 8 studies
reported the effect on development of symptomatic distal
DVTs,306,316,326,329,334,336,341,375 31 studies reported on risk of
major bleeding,295,305-307,311,313,315-319,321-339,341,344-346,374-377,379
and 19 studies reported on risk of reoperation.305,307,309,317,319,
322,323,326,329,330,333-337,341,375-377 To determine the desirable and
undesirable effects of prophylaxis in absolute terms, the baseline
risks specific for TURP outcomes obtained from a systematic
review by Tikkinen et al369 were applied to the corresponding
pooled RRs.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/59BDE78B-362E-9573-980D-41A280D79D9E.
Benefits. The risks of mortality may be similar for patients treated
with LMWH and UFH (RR, 1.03; 95% CI, 0.89-1.18; very low
certainty in the evidence of effects), but we are very uncertain of this
finding. Given an assumed baseline risk of 0.2%,370-372 this
corresponds to 0 fewer (0 fewer to 0 more) deaths per 1000
patients. Similarly, there may be little difference for other outcomes,
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such as symptomatic PEs (RR, 0.84; 95% CI, 0.59-1.20; very low
certainty in the evidence of effects), corresponding to 0 fewer (0 fewer
to 0 more) events per 1000 patients. We are equally uncertain about
the risk of symptomatic proximal DVTs (RR, 1.01; 95% CI, 0.20-5.0;
very low certainty in the evidence of effects) and symptomatic severe
distal DVTs (RR, 1.01; 95% CI, 0.30-3.44; very low certainty in the
evidence of effects). Corresponding absolute effect size estimates are
very small.
Harms and burden. The risks of bleeding may be similar with
LMWH and UFH (RR, 0.97; 95% CI, 0.78-1.20; low certainty in the
evidence of effects), corresponding to 0 fewer (4 fewer to 3 more)
major bleeding events per 1000 patients undergoing TURP. The
use of LMWH does not appear to decrease the risk of reoperation
(RR, 0.79; 95% CI, 0.57-1.08; low certainty in the evidence of
effects) for patients undergoing TURP. When applying a TURP-
specific baseline risk of 0.2%, this corresponded to 0 fewer (0-1
fewer) reoperations per 1000 patients undergoing TURP.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, indirectness, and very serious imprecision.
Other EtD criteria and considerations. The panel rated the
magnitude of the desirable effects and undesirable effects of using
LMWH or UFH as trivial. They further determined that there was
possibly important uncertainty and/or variability in how much
patients value the main outcomes. Overall, the balance of effects
did not favor LMWH or UFH, nor did cost-effectiveness or issues
surrounding equity, acceptability, and feasibility, at least for inpatient
prophylaxis. The panel recognized that this particular comparison
applied only to patients undergoing TURP considered at very high
risk for VTE (eg, patients with a history of VTE) in whom
pharmacological prophylaxis might be considered.
Conclusions and research needs for this recommendation.
Based on very low certainty in the evidence for effects, the guideline
panel did not find a net benefit for using LMWH or UFH for patients
undergoing TURP in whom pharmacological prophylaxis is indi-
cated and suggests that either can be used. For most patients
undergoing TURP, the panel recommended against the use of
pharmacological prophylaxis (see Recommendation 21). No
high-priority research needs were identified.
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients undergoing radical
prostatectomy?
Recommendation 23
For patients undergoing radical prostatectomy, the ASH
guideline panel suggests against using pharmacological pro-
phylaxis (conditional recommendation based on very low cer-
tainty in the evidence of effects Å◯◯◯). Remark: Patients
undergoing an extended node dissection and/or open radical
prostatectomy may have a higher VTE risk and may potentially
benefit from pharmacological prophylaxis.
Summary of the evidence. Because of the paucity of RCTs
specific to this setting, the evidence base to inform the relative
effectiveness of pharmacological prophylaxis vs no pharmacological
prophylaxis was comparable to that used to inform this question for
patients undergoing TURP (see Recommendation 21); we pooled
data across all surgical procedures and applied surgery-specific
baseline risk estimates for radical prostatectomy drawn from a
systematic review by Tikkinen et al.380
The EtD framework is available online at https://guidelines.gradepro.org/
profile/F99386B2-4C08-3F36-8029-61B51278B574.
Benefits. Pharmacological prophylaxis vs no prophylaxis may
not reduce mortality (RR, 0.75; 95% CI, 0.61 to 0.93; low
certainty in the evidence of effects), corresponding to 0 fewer
deaths per 1000 patients. Pharmacological prophylaxis proba-
bly does not reduce symptomatic PEs (RR, 0.48; 95% CI, 0.26-
0.88; moderate certainty in the evidence of effects). Depending on
patient risk, this corresponds to 0 fewer symptomatic PEs in lower-
risk patients to 0 fewer (0-1 fewer) symptomatic PEs per 1000
higher-risk patients undergoing radical prostatectomy. We are
very uncertain about the effect on symptomatic proximal DVTs
(RR, 0.38; 95% CI, 0.14-1.00; very low certainty in the evidence
of effects). This corresponds to 1 fewer (0-1 fewer) symptomatic
proximal DVT per 1000 lower-risk patients to 4 fewer (0-5 fewer)
per 1000 higher-risk patients. Distal DVTs may be reduced (RR,
0.52; 95% CI, 0.31-0.87; low certainty in the evidence of
effects), but this also corresponds to a negligible effect of
0 fewer symptomatic distal DVT events, irrespective of baseline
risk category.
Harms and burden. Pharmacological prophylaxis compared
with no prophylaxis may increase major bleeding (RR, 1.24;
95% CI, 0.87-1.77; low certainty in the evidence of effects).
This corresponds to 6 more (3 fewer to 20 more) major bleeding
events per 1000 patients undergoing radical prostatectomy.
We are uncertain about the effect of pharmacological prophylaxis
compared with no prophylaxis on reoperations (RR, 0.93; 95% CI,
0.35-2.50; very low certainty in the evidence of effects); this
corresponds to 0 fewer (3 fewer to 6 more) reoperations per 1000
men based on a baseline risk of 0.4%.380
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on
the lowest certainty in the evidence for the critical out-
comes, downgrading for study limitations, indirectness, and
imprecision.
Other EtD criteria and considerations. The panel recog-
nized during its deliberations that the practice of radical
prostatectomy varies greatly, ranging from robotically assisted
laparoscopic radical prostatectomy with no or a limited pelvic
lymph node dissection to open radical prostatectomy with
extended pelvic lymph node dissection. Based on a systematic
review by Tikkinen et al,380 this results in substantially different
baseline risks for VTEs, which are important considerations for
these recommendations. The majority of radical prostatectomies
performed by urologists in the United States are performed robotically,
typically with no or only a limited lymph node dissection. In this group,
the panel judged the desirable effects of pharmacological
prophylaxis as trivial and undesirable effects as small. Patients
undergoing open radical prostatectomy with lymph node
dissection were considered at higher risk for VTEs and bleeding.
Cost-effectiveness probably favored no pharmacological prophy-
laxis, whereas issues of equity, acceptability, and feasibility were not
deemed important in this setting.
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Conclusions and research needs for this recommendation.
The guideline panel judged that the net benefit favors no
pharmacological prophylaxis for patients undergoing radical
prostatectomy, based on very low certainty in the evidence of
effects. The panel perceived it as important to emphasize that
this recommendation was based on the panel’s assessment of
average patients undergoing radical prostatectomy in the form
of robotically assisted laparoscopic prostatectomy with no or
limited lymph node dissection. Patients undergoing an extended
node dissection and/or open radical prostatectomy may have a
higher VTE risk and may potentially benefit from pharmacological
prophylaxis. Further high-quality comparative studies, using appro-
priate clinical outcomes, would be of value to add more certainty
to these recommendations. Further studies on patient values
regarding prevention of VTEs and bleeding would allow for optimal
shared decision making regarding thromboprophylaxis for radical
prostatectomy.
Question: If pharmacological prophylaxis is indicated, should
LMWH vs UFH be used for patients undergoing radical
prostatectomy?
Recommendation 24
For patients undergoing radical prostatectomy in whom
pharmacological prophylaxis is used, the ASH guideline
panel suggests using either LMWH or UFH (conditional rec-
ommendation based on very low certainty in the evidence of
effects, (Å◯◯◯).
Summary of the evidence. In the absence of RCTs specific to
this setting, the evidence base to inform the relative effectiveness of
LMWH prophylaxis vs UFH prophylaxis was comparable to that
used to inform this question for patients undergoing TURP (see
Recommendation 22); we pooled data across all surgical
procedures and applied surgery-specific baseline risk estimates
for radical prostatectomy drawn from a systematic review by
Tikkinen et al.380
The EtD framework is available online at https://guidelines.gradepro.org/
profile/AEF71CF4-AB9F-1DDF-A08B-1F5E2484EA5F.
Benefits. The risks of mortality may be similar for patients treated
with LMWH and UFH (RR, 1.03; 95% CI, 0.89-1.18; low
certainty in the evidence of effects); this corresponds to 0 fewer
deaths per 1000 men. Similarly, there may be little difference for
the other outcomes of symptomatic PEs (RR, 0.84; 95% CI,
0.59-1.20; very low certainty in the evidence of effects),
symptomatic proximal DVTs (RR, 1.01; 95% CI, 0.20-5.0; very low
certainty in the evidence of effects), and symptomatic distal DVTs (RR,
1.01; 95% CI, 0.30-3.44; very low certainty in the evidence of effects),
with all 95% CIs crossing the line of no effect and very small absolute
effect sizes.
Harms and burden. The risks of bleeding may be similar with
LMWH and UFH (RR, 0.97; 95% CI, 0.78-1.20; low certainty in the
evidence of effects), corresponding to 0 fewer (4 fewer to 3 more)
major bleeding events per 1000 patients undergoing radical
prostatectomy. The risks of reoperation may be similar with LMWH
and UFH (RR, 0.79; 95% CI, 0.57-1.08; low certainty in the
evidence of effects), corresponding to 1 fewer (0-2 fewer) event
based on a baseline risk of 0.4%.380
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations, indirectness, and very serious imprecision.
Other EtD criteria and considerations. The panel rated the
magnitude of the desirable and undesirable effects of using LMWH
over UFH as trivial. They further determined that there was possibly
important uncertainty and/or variability in how much people value
the main outcomes. Overall, the balance of effects did not favor
LMWH or UFH, nor did cost-effectiveness or issues surrounding
equity, acceptability, and feasibility, at least for inpatient pro-
phylaxis. The panel recognized that this particular comparison
applied only to select patients undergoing radical prostatectomy
considered at high risk for VTEs (eg, patients with prior VTEs). For
most patients undergoing radical prostatectomy, the panel
recommended against the use of pharmacological prophylaxis
(see Recommendation 23).
Conclusions and research needs for this recommendation.
The guideline panel judged that, for patients undergoing radical
prostatectomy requiring pharmacological prophylaxis, based upon
very low certainty in the evidence, LMWH or UFH can be used.
There is a need for high-quality randomized trials specific to patients
undergoing radical prostatectomy, particularly those treated with
robotically assisted laparoscopic prostatectomy, the most widely
used surgical approach for clinically localized prostate cancer.
Cardiac or major vascular surgery
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients undergoing cardiac or
major vascular surgery?
Recommendation 25
For patients undergoing cardiac or major vascular surgery,
the ASH guideline panel suggests using pharmacological
prophylaxis or no pharmacological prophylaxis (conditional
recommendation based on very low certainty in the evidence
of effects Å◯◯◯).
Summary of the evidence. Our systematic search for RCTs
identified 3 studies70,381,382 that fulfilled our inclusion criteria and
measured outcomes relevant to this context. Because of the paucity
of RCTs, we also systematically searched for observational studies
and identified 1 additional study that fulfilled our inclusion criteria.383
One trial reported the effect of pharmacological prophylaxis vs
no intervention on risk of mortality.381 Two trials reported the effect
on the risk of symptomatic PEs and on the risk of any proximal and
distal DVTs.70,381,382 The effect on the risk of major bleeding was
reported from an RCT381 and a nonrandomized controlled study.383
Surgery-specific baseline risk estimates were obtained from a
systematic review and meta-analysis of risk of VTE after cardiac
surgery.384
The EtD framework is available online at https://guidelines.gradepro.org/
profile/D5319730-F947-FFB7-B1F7-D4E9E4697079.
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Benefits. We were unable to assess the effect of pharmacolog-
ical prophylaxis on mortality (RR, not estimable because no deaths
were observed, low certainty in the evidence of effects). Pharma-
cological prophylaxis appears to result in little or no difference in
symptomatic PEs (RR, 2.40; 95%CI, 0.10-55.7; low certainty in the
evidence of effects); this corresponds to 5 more (3 fewer to 198
more) PEs per 1000 patients receiving pharmacological prophylaxis
based on a baseline risk of 0.4%.384 We are very uncertain whether
pharmacological prophylaxis results in little or no difference in
proximal DVTs (RR, 2.85; 95% CI, 0.12-67.83; low certainty in the
evidence of effects). This finding corresponds to 45 more (21 fewer
to 1631 more) symptomatic proximal DVTs per 1000 patients,
based on a baseline risk of 2.4%.384 We are also very uncertain
about the effect of pharmacological prophylaxis on distal DVTs (RR,
0.32; 95% CI, 0.01-7.54; very low certainty in the evidence of
effects). This corresponds to 1 fewer (2 fewer to 13 more)
symptomatic distal DVT per 1000 high-risk patients, based on a
baseline risk of 0.2%.384
Harms and burdens. Based on 1 large observational study383
and supported by a single relevant RCT,381 the rates of major
bleeding may be increased with pharmacological prophylaxis (RR,
1.26; 95%CI, 1.07-1.47; low certainty in the evidence of effects). This
corresponds to 4 more (1-6 more) major bleeds per 1000 patients.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes informed by
observational studies.
Other EtD criteria and considerations. The panel recog-
nized that very high doses of UFH are routinely administered to
most patients undergoing cardiac and major vascular surgery.
Thus, for this recommendation, the benefits and harms of
postoperative pharmacological prophylaxis are being considered
in an incremental context. The panel recognized there was a paucity
of high-quality evidence addressing this particular question, and this
recommendation was made in the face of very uncertain evidence.
Based upon available evidence, the panel judged that the incremental
desirable and undesirable effects of pharmacological prophylaxis
were trivial and, therefore, balanced.
The panel recognized that cardiac surgery itself is associated with
a risk for the development of heparin-induced thrombocytopenia
(HIT). The panel reviewed the available literature and found that the
risk of HIT among heparin preparations was higher with the use of
UFH than with LMWH. Available evidence from RCTs did not allow
the panel to quantitate whether there was an incremental risk for
HIT associated with the use of pharmacological heparin prophylaxis
beyond that of UFH administered during the procedure itself.
However, the panel acknowledged that concerns about HIT would
lead some panelists to be less likely to routinely use postoperative
pharmacological prophylaxis with a heparin preparation, particularly
UFH. The panel did not believe that there were important implementa-
tion considerations with the use of postoperative pharmacological
prophylaxis in this patient population. Should LMWH or UFH be given,
the panel recommended periodic monitoring of platelet counts
because of the concern for postoperative HIT.
Conclusions and research needs for this recommendation.
The panel found that the overall net benefit did not favor pharmaco-
logical prophylaxis or no pharmacological prophylaxis for patients
undergoing cardiac and major vascular surgery; this was based on
very low certainty in the evidence. For subgroup considerations, the
panel judged that, for patients at higher baseline risk for VTE (eg,
those with a history of VTE), pharmacological prophylaxis might be
considered over no prophylaxis.
The panel supported that further research, in the form of well-
designed RCTs using clinically important end points, is needed
to determine the role of pharmacological prophylaxis in the preven-
tion of VTEs following cardiac and major vascular surgery. Further
research on the incremental impact of postoperative UFH and
LMWH exposure on the development of HIT in this patient
population is also warranted.
Question: Should LMWH prophylaxis vs UFH prophylaxis be used
for patients undergoing cardiac or major vascular surgery?
Recommendation 26
When pharmacological prophylaxis is used for patients undergoing
cardiac or major vascular surgery, the ASH guideline panel
suggests using LMWH or UFH (conditional recommendation
based on very low certainty in the evidence of effects Å◯◯◯).
Summary of the evidence. We identified 1 systematic review385
of RCTs and observational studies that addressed this research
question.We identified 3 studies386-388 in these reviews that fulfilled our
inclusion criteria and measured outcomes relevant to this context. Our
update of the systematic review did not identify any additional
studies that fulfilled the inclusion criteria. One study reported the
effect of LMWH vs UFH on the risk of mortality, PE, and major
bleeding.387 Three studies reported the effect of LMWH vs UFH on
the risk of any DVT, including 1 study reporting data for proximal and
distal DVTs separately.386-398
Surgery-specific baseline risk estimates were obtained from a system-
atic review and meta-analysis of risk of VTEs after cardiac surgery.384
The EtD framework is available online at https://guidelines.gradepro.org/
profile/D32EF371-AE1E-1ACF-82CD-E11528E7B8E0.
Benefits. We are very uncertain whether LMWH vs UFH affects
mortality following cardiac or major vascular surgery (RR, 4.55; 95%
CI, 0.22-93.81; low certainty in the evidence of effects). This
corresponds to 0 fewer deaths per 1000 patients. We were unable
to estimate an effect on symptomatic PEs (RR, not estimable). We are
also very uncertain about the effect of LMWHon symptomatic proximal
DVTs (RR, 1.33; 95% CI, 0.30-6.01; very low certainty in the evidence
of effects) and symptomatic distal DVTs (RR, 1.20; 95%CI, 0.45-3.22;
very low certainty in the evidence of effects). This would correspond to 8
more (17 fewer to 122 more) symptomatic proximal DVTs per 1000
patients and 0 more (1 fewer to 4 more) symptomatic distal DVTs per
1000 patients based on baseline risks of 2.4% and 0.2%, respectively.
Harms and burden. LMWH vs UFH appears to result in little or no
difference in major bleeding (RR, 0.91; 95% CI, 0.19-4.42; low
certainty in the evidence of effects). We found no data on reoperation.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
indirectness and very serious imprecision.
Other EtD criteria and considerations. The panel recog-
nizes that they have judged that evidence was insufficient and of
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very low quality to recommend for or against pharmacological
prophylaxis following cardiac surgery. Nevertheless, particularly for
patients considered at high risk for VTE (eg, those with history of
VTEs), postoperative pharmacological prophylaxis would be consid-
ered for use in the cardiac and major vascular surgery settings by
some panelists. This recommendation is relevant for patients
considered at high risk for VTEs.
As discussed in the previous recommendation, HIT is a recognized
complication in the cardiac and vascular surgery settings. Furthermore,
it is recognized that the risk of HIT in other settings has been shown to
be higher with the use of UFH vs LMWH. Available evidence from
RCTs did not allow the panel to quantitate whether there was an
incremental risk for HIT associated with the use of pharmacological
UFH or LMWH prophylaxis beyond that of heparin administered
during the procedure itself or whether there was a relatively greater
incremental risk for HIT in the cardiac surgery setting with post-
operative UFH prophylaxis than with LMWH. Nevertheless, given the
above factors, if pharmacological prophylaxis is chosen for use,
panelists concurred that an anticoagulant with a lower risk for HIT
(eg, LMWH over UFH) should be considered.
The panel did not believe that there were important implementation
considerationswith use of postoperative LMWHorUFHpharmacological
prophylaxis in this patient population. Should either agent be given, the
panel recommended the periodic monitoring of platelet counts.
Conclusions and research needs for this recommendation.
The panel judged that, based upon available evidence, LMWH or UFH
could be selected for VTE prophylaxis following cardiac surgery based on
very low quality evidence. The panel judged that this question was only
of relevance for patients considered at very high risk for postoperative
VTEs following cardiac or major vascular surgery in whom pharmaco-
logical prophylaxis would be considered over no prophylaxis.
The panel supported that the more important research question for
this patient population is the role of pharmacological prophylaxis vs
no pharmacological prophylaxis for the prevention of VTEs following
cardiac andmajor vascular surgery. Further research on the incremental
impact of postoperative UFH and LMWHexposure on the development
of HIT in this patient population would also be of value.
Major trauma
Question: Should pharmacological prophylaxis vs no pharmaco-
logical prophylaxis be used for patients experiencing major trauma?
Recommendation 27a
For patients experiencing major trauma at low to moderate risk
for bleeding, the ASH guideline panel suggests using pharma-
cological prophylaxis (conditional recommendation based on
very low certainty in the evidence of effects Å◯◯◯).
Recommendation 27b
For patients experiencing major trauma at high risk for bleeding,
the ASH guideline panel suggests against pharmacological
prophylaxis (conditional recommendation based on very low
certainty in the evidence of effects Å◯◯◯).
Summary of the evidence. We identified 1 systematic review
that addressed this question.389We identified 2 studies47,390 in this
review that fulfilled our inclusion criteria and measured outcomes
relevant to this context. Our update of the systematic review did
not identify any additional studies that fulfilled the inclusion criteria.
Two small studies reported the effect of pharmacological pro-
phylaxis compared with no intervention on risk of mortality, on
development of symptomatic PEs, and on any DVT.47,390 No study
reported the effect of pharmacological prophylaxis compared with no
intervention on risk of major bleeding or on risk of reoperation. The
small amount of direct evidence, with a lack of information on
undesirable outcomes, together with the very low certainty on the
treatment effect, led the panel to consider the indirect data from hip
fracture repair studies for treatment RR estimates255-266 and
applying baseline VTE and bleeding risks from studies on trauma
patients.391,392
The EtD framework is available online at https://guidelines.gradepro.org/
profile/434A9C2D-3417-F3ED-B7C1-4A0BA3EC6699.
Benefits. We are uncertain about the effect of pharmacological
prophylaxis on mortality following major trauma (RR, 0.95; 95% CI,
0.84-1.07; very low certainty in the evidence of effects).
Pharmacological prophylaxis may reduce symptomatic PEs, but
we are very uncertain of this finding (RR, 0.49; 95% CI, 0.33-0.72;
very low certainty in the evidence of effects). Depending upon
baseline risk, this benefit corresponds to 3 fewer (2-5 fewer)
patients with symptomatic PEs per 1000 moderate-risk patients
and 2 fewer (1-2 fewer) patients per 1000 low-risk patients.
Pharmacological prophylaxis may also reduce the risk of proximal
DVTs (RR, 0.51; 95% CI, 0.38-0.69; very low certainty in the
evidence of effects), which corresponds to 7 fewer (4-9 fewer)
in 1000 higher-risk patients and 3 fewer (2-4 fewer) in 1000 lower-
risk patients. We are uncertain of the effect of pharmacological
prophylaxis on distal DVTs (RR, 0.85; 95% CI, 0.5-1.29, very low
certainty in the evidence of effects). This would correspond to
1 fewer (3 fewer to 2 more) symptomatic distal DVT in 1000 higher-
risk patients and 0 fewer in 1000 lower-risk patients.
Harms and burden. Pharmacological prophylaxis may result in
more major bleeding than no prophylaxis (RR, 1.24; 95% CI, 1.12-
1.37; very low certainty in the evidence of effects), but this finding is
uncertain. Depending upon baseline risk, the risk of major bleeding
corresponds to 3 more (2-5 more) major bleeds per 1000 lower-
bleeding-risk patients and to 14 more (7-21 more) major bleeds per
1000 patients with higher bleeding risk.
We are very uncertain about the effect of pharmacological prophylaxis
on the need for reoperation (RR, 1.05; 95% CI, 0.82-1.35; very low
certainty in the evidence of effects).
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the
lowest certainty in the evidence for the critical outcomes,
downgrading for study limitations, indirectness, and imprecision.
Other EtD criteria and considerations. The overall certainty
in the evidence was rated as very low for this question, given the
absence of RCTs comparing pharmacological prophylaxis vs no
prophylaxis for patients experiencing major trauma. The benefits
and harm/burden data were extrapolated from the closest
surgical indication for which we had adequate comparative
evidence (ie, hip fracture repair). It is recognized that these hip
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fracture studies are dated and that rates of patient-important DVT
events were derived from modeling of asymptomatic events detected
by routine screening studies. The panel presumed that, in the absence
of specific contraindications (eg, lower limb injuries), patients
experiencing major trauma would receive mechanical prophylaxis.
The panel emphasized the need to periodically reevaluate bleeding risk
as patients recover from major trauma. Once bleeding is stabilized and
the patient is no longer considered at high risk for major bleeding, the
use of pharmacological prophylaxis should be reconsidered.
Conclusions and research needs for this recommendation.
Based upon the totality of the evidence, the panel judged that
the moderate overall benefits of pharmacological prophylaxis
outweighed the increased risk of major bleeding for patients at
low or moderate risk for bleeding. In contrast, for patients at high
risk for major bleeding, the large undesirable consequences of
major bleeding led to a balance that favors no pharmacological
prophylaxis. The very low certainty in the evidence justifies conditional
recommendations for both scenarios.
Well-designed trials using clinically important VTE end points are
required for patients at low to moderate risk for bleeding following
trauma to determine the incremental benefits of pharmacological
prophylaxis beyond mechanical methods alone. Well-designed studies
are also needed to determine the benefits and risks of introducing
delayed pharmacological prophylaxis for patients experiencing major
bleeding, including intracranial hemorrhage as a consequence of
major trauma, as the bleeding risk subsides.
Question: Should LMWH vs UFH be used for patients experienc-
ing major trauma?
Recommendation 28
For patients experiencing major trauma in whom pharmaco-
logical prophylaxis is used, the ASH guideline panel suggests
using LMWH or UFH (conditional recommendation based on
low certainty in the evidence of effects ÅÅ◯◯).
Summary of the evidence. We identified 1 systematic review
that addressed this question.389 Our update of the systematic
review identified 1 additional study that fulfilled the inclusion
criteria,394 and our systematic search of RCTs identified 2 studies
that fulfilled the inclusion criteria394,395 and were not included in the
review. Three studies reported the effect of LMWH prophylaxis vs
UFH prophylaxis on risk of mortality, on development of any PEs,
and on major bleeding,393-395 whereas 2 studies informed on the
risk of development of proximal and distal DVTs.393,394
The EtD framework is available online at https://guidelines.gradepro.org/
profile/96D5A309-8606-4469-B732-E1844465CC75.
Benefits. LMWH vs UFH appears to result in little or no
difference in mortality for patients experiencing major trauma (RR,
1.32; 95% CI, 0.14-12.39; low certainty in the evidence of effects).
This corresponds to 2 more (4 fewer to 54 more) deaths per 1000
trauma patients receiving LMWH vs UFH. Similarly, LMWH may
result in little or no difference in symptomatic PEs (RR, 1.04; 95%
CI, 0.11-9.92; low certainty in the evidence of effects). This
corresponds to 0 fewer (6 fewer to 61 more) symptomatic PEs per
1000 patients based on a baseline risk of 0.7% from observational
data.391 LMWH vs UFH likely results in no important effect on
proximal DVTs (RR, 0.57; 95% CI, 0.25-1.31; moderate certainty in
the evidence of effects). This corresponds to 3 fewer (5 fewer to 2
more) symptomatic proximal DVTs per 1000 patients based on a
baseline risk of 0.7% from observational data.391
LMWH probably also results in little or no difference in symptomatic
distal DVTs (RR, 0.74; 95%CI, 0.46-1.20; moderate certainty in the
evidence of effects). This corresponds to 0 fewer symptomatic
distal DVTs per 1000 patients based on a baseline risk of 0.1% from
observational data.391
Harms and burden. LMWH may result in a small increase in
major bleeding (RR, 2.4; 95% CI, 0.53-10.78; low certainty in the
evidence of effects). This corresponds to 20 more (7 fewer to 138
more) major bleeding events per 1000 patients receiving LMWH vs
UFH. There were no comparative data about rates of reoperation of
LMWH vs UFH following major trauma.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
very serious imprecision.
Other EtD criteria and considerations. The panel judged that
the minor differences in the effects of the interventions on benefits and
undesirable outcomes led to an overall balance that did not favor either
intervention. The benefits observed with LMWHwere limited to a minor
reduction in the rates of symptomatic proximal DVTs, which was
negated by the small observed increased risk of major bleeding. It was
recognized that patients at high risk for major bleeding were excluded
from the studies that formed the basis of this recommendation.
Because LMWHandUFHare inwidespread use for this indication, the
panel did not judge there to be major implementation considerations
with either intervention. The panel presumed that, in the absence of
specific contraindications (eg, lower limb injuries), patients experi-
encing major trauma would receive mechanical prophylaxis.
Conclusions and research needs for this recommendation.
The panel suggested that, for patients experiencing major trauma
who are judged to be at low to moderate risk for bleeding, LMWH or
UFH may be used for pharmacological VTE prophylaxis based on
low certainty in the evidence.
The panel judged that the research priorities in major trauma related
to establishing the effectiveness and the timing of intervention
with pharmacological prophylaxis for patients receiving mechan-
ical prophylaxis following major trauma, rather than comparative
studies of LMWH vs UFH.
Major gynecological surgery
Question: Should pharmacological prophylaxis vs no pharmacolog-
ical prophylaxis be used for patients undergoing major gynecological
surgery?
Recommendation 29
For patients undergoing major gynecological surgery, the ASH
guideline panel suggests using pharmacological prophylaxis
over no pharmacological prophylaxis (conditional recommen-
dation based on very low certainty in the evidence of effects
Å◯◯◯).
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Summary of the evidence. We identified 1 systematic review
of RCTs addressing this research question.29 We identified only 5
studies118,273-275,349 in this review that fulfilled our inclusion criteria
and measured outcomes relevant to this context. Because of the
paucity of studies on patients undergoing major gynecological
procedures, data across major general, laparoscopic cholecys-
tectomy, and major gynecological and urological procedures
were pooled. The evidence base to inform the relative
effectiveness of pharmacological prophylaxis vs no pharmaco-
logical prophylaxis was comparable to that used to inform this
question for patients undergoing laparoscopic cholecystectomy (see
Recommendation 18). Baseline risk estimates specific to gyneco-
logical procedures396,397 were applied to determine the desirable
and undesirable effects of prophylaxis in absolute terms.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/B2FDFE66-5A79-4E46-875E-9BB7F3FAFF9F.
Benefits. Pharmacological prophylaxis probably reduces mor-
tality slightly following major gynecological surgery (RR, 0.75;
95% CI, 0.61-0.93; low certainty in the evidence of effects).
This corresponds to a benefit of 4 fewer (1-7 fewer) deaths per
1000 patients. Pharmacological prophylaxis probably reduces the
risk of symptomatic PEs (RR, 0.48; 95% CI, 0.26-0.88; low certainty
in the evidence of effects), corresponding to a benefit of 2 fewer
(0-3 fewer) symptomatic PEs per 1000 higher-risk patients
and 0 fewer (0-1 fewer) per 1000 lower-risk patients, based
on baseline risks from observation data of 0.1% and 0.4%,
respectively.396,397
We are uncertain whether pharmacological prophylaxis reduces the
rates of proximal DVTs (RR, 0.38; 95% CI, 0.14-1.00; very low
certainty in the evidence of effects), corresponding to reduction of
4 fewer (0-6 fewer) symptomatic proximal DVTs per 1000 lower-risk
patients and 17 fewer (0-23 fewer) per 1000 higher-risk patients
based on baseline risks from observation data of 0.7% and 2.7%,
respectively.396,397 We are uncertain about the effect of pharma-
cological prophylaxis on distal DVTs (RR, 0.52; 95%CI, 0.31-0.87;
low certainty in the evidence of effects), corresponding to no
reduction per 1000 patients treated based on a lower baseline risk
of 0.1%.
Harms and burden. Pharmacological prophylaxis may slightly
increase the risk of major bleeding (RR, 1.24; 95% CI, 0.87-1.77;
low certainty in the evidence of effects). This corresponds to 6 more
(3 fewer to 20 more) major bleeding events per 1000 patients
receiving pharmacological prophylaxis. Pharmacological pro-
phylaxis does not appear to increase the risk of reoperation (RR,
0.93; 95% CI, 0.35-2.50; very low certainty in the evidence of
effects) following major gynecological procedures.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading
for study limitations, indirectness, and imprecision.
Other EtD criteria and considerations. The panel based its
recommendation on the judgment that the desirable benefits of
pharmacological prophylaxis outweighed the likely small in-
creased risk of major bleeding following major gynecological
procedures. The panel acknowledges that the overall certainty in
the evidence was very low given the issue of indirectness, with
most of the available trial data not being specific to gynecological
procedures. The panel considered that patients at increased risk for
VTE would receive mechanical prophylaxis in addition to pharma-
cological prophylaxis. There were no major implementation
considerations.
Conclusions and research needs for this recommendation.
The panel judged that pharmacological prophylaxis should be
administered to patients undergoing major gynecological sur-
gery, and this recommendation was conditional given the very low
certainty in the evidence. There is a need for large high-quality
clinical trials using clinically relevant end points to determine the
benefit of pharmacological prophylaxis following gynecologi-
cal procedures. These studies should include detailed clinical
characteristics of the patient populations.
Question: Should LMWH vs UFH prophylaxis be used for patients
undergoing major gynecological surgery?
Recommendation 30
For patients undergoing major gynecological surgery, the ASH
guideline panel suggests using LMWH or UFH (conditional
recommendation based on very low certainty in the evidence
of effects Å◯◯◯).
Summary of the evidence. We identified 1 systematic review
of RCTs addressing this research question.30 We identified only 4
studies374,376,377,379 overall that were conducted with patients
undergoing major gynecological surgery. Because of the paucity
of studies on patients undergoing major gynecological proce-
dures, data across major general, laparoscopic cholecystectomy,
and major gynecological and urological procedures were pooled.
The evidence base to inform the relative effectiveness of LMWH
prophylaxis vs UFH prophylaxis was comparable to that used to
inform this question for patients undergoing TURP (see Recom-
mendation 22).
Baseline risk estimates specific to gynecological procedures396,397
were applied to determine the desirable and undesirable effects of
prophylaxis in absolute terms.
The EtD framework is available online at https://guidelines.gradepro.org/
profile/F213C6D1-F2D9-221A-B8EE-92B6F94F5BB3.
Benefits. LMWH prophylaxis appears to result in little or no
difference in mortality compared with UFH prophylaxis (RR,
1.03; 95% CI, 0.89-1.18; low certainty in the evidence of
effects), corresponding to 1 more (2 fewer to 3 more) deaths
per 1000 patients. Likewise, use of LMWH prophylaxis vs UFH
prophylaxis appears to result in little or no difference in
symptomatic PEs (RR, 0.91; 95% CI, 0.63-1.3; low certainty
in the evidence of effects). For a higher baseline risk of 0.4%
from observational data,396 this corresponds to 1 fewer (2 fewer
to 1 more) symptomatic PE per 1000 participants. For
symptomatic proximal DVTs (RR, 1.01; 95% CI, 0.20-5.00;
low certainty in the evidence of effects), the absolute risk
reduction is 0 per 1000 patients, with the 95% CI varying by
baseline risk from 5 fewer to 27 more397 to 22 fewer to 108 more
(baseline risks of 0.7% and 2.7%, respectively).396 We are very
uncertain about the effect on symptomatic distal DVTs (RR,
1.01; 95% CI, 0.30-3.44; very low certainty in the evidence of
effects) following major gynecological surgical procedures.
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Harms and burden. LMWH appears to confer little or no
difference in major bleeding compared with UFH prophylaxis
following major gynecological procedures (RR, 0.97; 95% CI,
0.78-1.20; low certainty in the evidence of effects); this
corresponds to 0 fewer (4 fewer to 3 more) major bleeds per
1000 patients. LMWH prophylaxis may result in a small, possibly
unimportant, reduction in reoperations compared with UFH (RR,
0.79; 95% CI, 0.57-1.08; low certainty in the evidence of effects).
This corresponds to 4 fewer (8 fewer to 1 more) reoperation
procedures per 1000 patients receiving LMWH prophylaxis.
Certainty in the evidence of effects. We rated the overall
certainty in the evidence of effects as very low based on the lowest
certainty in the evidence for the critical outcomes, downgrading for
study limitations and indirectness.
Other EtD considerations. The panel based its recommenda-
tion on the judgment that the desirable benefits and the risk of
complications were balanced between use of LMWH and UFH
pharmacological prophylaxis. The panel acknowledges that the
overall certainty in the evidence was very low, given the issue of
indirectness, with most of the available trial data not being specific
to gynecological procedures. There was not deemed to be any
major implementation consideration.
Conclusions and research needs for this recommendation.
The panel suggests using LMWH or UFH for patients undergo-
ing major gynecological surgery procedures based upon very low
certainty in the evidence of effects. There is a need for large high-
quality clinical trials using clinically relevant end points to determine
the relative benefits of LMWH vs UFH pharmacological prophylaxis
following gynecological procedures. These studies should include
detailed clinical characteristics of the patient populations.
Limitations of these guidelines
The panel recognized that many studies of pharmacological and
mechanical prophylaxis for VTE prevention following major surgery
date back decades, thereby raising questions about the applicabil-
ity of this evidence. This includes largely outdated means (eg,
venography) to assess for VTEs postoperatively. Surgical practice
has changed considerably over the decades, aimed at improving
the patient experience. In most circumstances, these innovations
would be expected to reduce the overall risk of postoperative VTEs.
Examples of such innovations include use of minimally invasive
surgical procedures, early and increased postoperative patient
mobilization, and use of regional anesthesia; however, it is
uncertain whether such changes in surgical practice impact the
relative effectiveness of various thromboembolic interventions.
Therefore, for the purpose of this guideline, this type of evidence
informing the relative effectiveness of these interventions was
included when obtained in the setting of RCTs. For determining
baseline risk of VTEs and major bleeding, we used data, where
available, from contemporary large cohort studies that were
deemed representative of contemporary patients.
Although the panel rated symptomatic VTE end points as those
upon which recommendations should be based, the panel recog-
nized that most studies of VTE prophylaxis following surgery used
asymptomatic DVTs detected by the routine performance of
sensitive screening tests (eg, venography) as the primary study
outcome. Reporting of symptomatic DVTs in some studies could
have been influenced by diagnostic suspicion bias. The panel
also acknowledges that modeling was required to determine
rates of symptomatic DVTs when only asymptomatic DVT events
were reported, based on the best available estimates drawn from
the literature.
The panel recognized that most of the evidence on mechanical
methods of VTE prophylaxis comes from the orthopedic literature.
Studies of the benefits of mechanical prophylaxis for other surgical
settings are needed. Finally, the panel acknowledges that, for some
questions, limited direct data were available (eg, VTE prophylaxis
following urological and gynecological procedures and for major
trauma). In these settings, estimates of the benefits of prophylaxis
were based upon related surgical settings, such as general surgical
procedures and hip fracture surgery, respectively.
What are others saying and what is new in
these ASH guidelines?
These ASH guidelines stand out by their scope, which includes
general issues relevant to any surgical procedure and those related
to surgical subspecialties. They make consistent use of high-quality
systematic reviews and provide a formal EtD framework for every
recommendation, thereby enhancing transparency about the
judgments that were made.
A widely used high-quality guideline is the 2012 Guideline of the
American College of Chest Physicians (ACCP), which places a
strong emphasis on patients’ VTE risk scores.398 In the guideline
recommendations for VTE prevention in nonorthopedic surgical
patients, patient-oriented VTE risk calculators, such as the Caprini
score10 and Rogers score,399 were adopted. When the risk for VTE
is very low, it was recommended not to use pharmacological or
mechanical prophylaxis. For patients at low risk for VTE, mechanical
prophylaxis was suggested over no prophylaxis, preferably with
intermittent pneumatic compression. For patients at moderate risk
for VTE who are not at high risk for major bleeding complications,
it was suggested to use LMWH, low-dose UFH, or mechanical
prophylaxis with intermittent pneumatic compression over no
prophylaxis. For patients at high risk for VTE who are not at high
risk for major bleeding complications, it was recommended to use
pharmacological prophylaxis with LMWH or low-dose UFH over
no prophylaxis, and it was suggested to add mechanical prophylaxis
with graduated compression stockings or intermittent pneumatic
compression to pharmacological prophylaxis. Guidelines by the
Scottish Intercollegiate Guidelines Network (SIGN) and the
National Institute for Clinical Excellence (NICE) also emphasize
the importance of risk stratification.400,401
Mechanical methods of perioperative VTE prophylaxis have been
addressed by a number of guidelines.398,400-404 The 2012 ACCP
guidelines did not provide a detailed comparison of the effective-
ness of graduated compression stockings and pneumatic com-
pression stockings, but they generally favor pneumatic compression
stockings on the basis of indirect evidence, from the Clots in Legs
or Stockings after Stroke trial for patients with stroke, that elastic
stockings increased the risk of skin complications without reducing
the risk of VTEs.405 Other guidelines presented by SIGN,400 NICE,401
the American Academy of Orthopedic Surgeons (AAOS),402 the
Neurocritical Society,404 and the International Union of Angiology403
discuss the use of pneumatic compression and graduated compres-
sion stockings in various surgical settings but generally consider these
modalities together as “mechanical devices” and do not offer a
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direct comparison of their effectiveness or safety other than noting
that graduated compression stockings cannot be used for patients
with certain lower extremity pathologies.
Guidelines addressing the prophylactic placement of IVC filters
include the 2012 ACCP guidelines,398 the 2011 AAOS guideline
for orthopedic patients,402 the 2013 European Venous Forum,403
the 2013 guidelines by the Neurocritical Care Society,404 the 2013
British Committee for Standards in Hematology guidelines, and the
“appropriateness criteria” by the American College of Radiology.406
The recommendation made by these ASH guidelines corresponds
with many of these existing recommendations that are mostly critical
of prophylactic IVC filter placement for patients requiring major
surgery or who have experienced trauma.
Several recent guidelines comment on VTE prophylaxis after
total hip or knee arthroplasty. The 2012 ACCP guideline for
orthopedic surgery patients407 recommended LMWH, fondapar-
inux, apixaban, dabigatran, rivaroxaban, low-dose UFH, adjusted-
dose vitamin K antagonists (VKAs), ASA, and/or intermittent
pneumatic compression, with the proviso that they are portable,
out of concerns regarding compliance. They further indicate
a preference for LMWH over the other listed agents, with the
exception of ASA. The 2011 AAOS guideline402 recommends
some form of chemoprophylaxis (including ASA) along with
intermittent pneumatic compression after total hip or knee arthro-
plasty. The 2012 Asian Venous Thromboembolism Guideline408
recommends LMWH, fondaparinux, rivaroxaban, apixaban, edox-
aban, dabigatran, warfarin, or ASA with intermittent pneumatic
compression, referencing and effectively accepting the 2012
ACCP and 2011 AAOS guidelines. The 2013 International
Angiology guideline favors LMWH, fondaparinux, VKAs, rivaroxaban,
apixaban, or dabigatran, along with use of intermittent pneumatic
compression after total hip arthroplasty.403 The most current
NICE guideline recommends LMWH or rivaroxaban after total hip
arthroplasty and the same after total knee arthroplasty, with the
additional option of ASA.401
For VTE prophylaxis after surgery for hip fractures, the 2012 ACCP
guideline recommends LMWH for VTE prophylaxis vs fondaparinux
and low-dose UFH over adjusted-dose VKAs or ASA.407 Concur-
rent use of an intermittent pneumatic compression device was also
recommended. The 2011 AAOS guideline does not specifically
address hip fractures; however, in the face of hip arthroplasty as a
treatment for hip fracture, their recommendations of some form of
chemoprophylaxis (including ASA), along with intermittent pneu-
matic compression for total hip arthroplasty, would be applica-
ble.402 The 2012 Asian Venous Thromboembolism Guideline
recommended LMWH, fondaparinux, rivaroxaban, apixaban, edox-
aban, dabigatran, warfarin, or ASA with intermittent pneumatic
compression.408 The Agency for Healthcare Research and
Quality 2017 guideline favors chemoprophylaxis but is neutral
on specific agents because of a lack of evidence.236 The 2013
International Angiology Guideline favors LMWH, fondaparinux,
VKAs, or low-dose UFH.403 The most current NICE guideline
recommends LMWH or fondaparinux.401
For general and abdominal surgery, which includes gastrointestinal,
urological, gynecological, bariatric, vascular, plastic, or recon-
structive surgery in its scope, the 2012 ACCP guidelines are once
again the best known. In the very low risk setting, no specific
pharmacological or mechanical prophylaxis is recommended other
than early ambulation. At low risk, mechanical prophylaxis (prefer-
ably with intermittent pneumatic compression) is suggested over no
prophylaxis. For moderate-risk patients, assuming there is no high
risk for major bleeding, LMWH, low-dose UFH, and mechanical
prophylaxis, preferably with intermittent pneumatic compression
devices, are all options. If patients are at high risk for major bleeding
complications or if consequences of bleeding are thought to be
particularly severe, mechanical prophylaxis (preferably with in-
termittent pneumatic compression devices) is suggested over no
prophylaxis.398
For patients undergoing neurosurgical procedures, there are a total
of 6 guidelines that offer somewhat conflicting recommendations
on pharmacological VTE prophylaxis. These guidelines include the
2012 ACCP guideline, the 2014 Korean Society of Thrombosis and
Hemostasis Evidence-Based Clinical Practice Guidelines, the 2018
NICE guideline, the 2010 SIGN guideline, the 2017 European
Society of Anesthesiology guideline, and the 2016 Neurocritical
Care Society guidelines.398,400,401,404,409,410 The recommenda-
tions provided by these current ASH guidelines are similar to the
2010 SIGN guidelines, the 2019 Congress of Neurological
Surgeons Guidelines for Spine Trauma, and the 2012 ACCP
guidelines. Overall, mechanical prophylaxis is recommended for
most neurosurgical patients. The benefit of pharmacological
prophylaxis should be considered for patients at high risk or very
high risk for VTE, but the overall risk/benefit profile is question-
able, given an increase in bleeding events, particularly because
neurosurgical bleeding events can be more serious. Similar to
the 2010 SIGN recommendations, our ASH guidelines suggest
that, for patients who do receive pharmacological prophylaxis,
LMWH be used over UFH, whereas the 2012 ACCP guidelines
do not give preference to any specific drug.
Urology is covered within the scope of guidelines by the ACCP, the
Australian National Health and Medical Research Council, and the
National Institute for Health and Care Excellence, among others.411
Urology-specific guidelines are available from the American
Urological Association, the German Association of Scientific
Medical Societies, and, most recently, the European Associa-
tion of Urology.412-414 In the absence of direct evidence for
urology, the European Association of Urology guideline makes
the assumption of a 50% risk reduction for “any serious VTE
event” as well as a 50% increase in the risk of major bleeding
requiring reoperation. When assessing the net benefit in making
the recommendation, the major bleeding was given twice the
weight of the outcome of VTE prevention. The resulting recommen-
dations were supported by a systematic review of the procedure-
specific VTE risk and the bleeding risk.369,380 For patients undergoing
TURP, this resulted in a conditional recommendation against
pharmacological prophylaxis across risk groups. For radical prosta-
tectomy, the guideline provides a more nuanced set of recommen-
dations that differ by surgical approach (open, laparoscopic, or
robotically assisted laparoscopic) and extent of the node dissection
(without, standard, or extended). For patients undergoing robotically
assisted laparoscopic prostatectomy with a standard lymph node
dissection, which was considered the index case for these ASH
guidelines, there is a conditional recommendation against pharma-
cological prophylaxis.
For cardiac surgery patients with an uncomplicated postopera-
tive course, the 2012 ACCP guideline suggested the use of
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mechanical prophylaxis, preferably with optimally applied intermit-
tent pneumatic compression, over no prophylaxis or pharmacolog-
ical prophylaxis.398 For cardiac surgery patients whose hospital
course is prolonged by $1 nonhemorrhagic surgical complication,
the guideline suggested adding pharmacological prophylaxis with
UFH or LMWH to mechanical prophylaxis. They considered that the
risk of VTE following cardiac surgery is uncertain but judged that
most patients were at moderate risk for VTEs and at high risk
for anticoagulant prophylaxis-related bleeding. Based on these
considerations, it was concluded that, in cardiac patients at usual
risk for VTE, the harms of anticoagulant prophylaxis outweighed the
benefits, whereas anticoagulation may be of net benefit for patients
with high-risk characteristics. The ACCP guidelines did not provide
recommendations specific to major vascular surgery. The Interna-
tional Consensus Statement on Prevention and Treatment of
Venous Thromboembolism published by the European Venous
Forum, in cooperation with several other organizations, offers
guidelines for general, vascular, bariatric, and plastic surgical
patients.403 Major vascular surgery was considered with other
“major surgery,” and patients were judged to generally be at
moderate risk in the absence of specific high-risk characteristics,
such as age older than 60 years or prior VTE. Pharmacological
prophylaxis was recommended in the absence of unusual bleeding
risks. Recommendations specific to cardiac surgery patients were
not presented. An update of NICE guidelines published in 2018
offers guidelines regarding VTE prophylaxis for patients undergoing
cardiac or major vascular surgery.401 This guideline recommends
considering mechanical VTE prophylaxis on admission for patients
who are undergoing cardiac surgery and are at increased risk for
VTE and continuing this until the patient no longer has significantly
reduced mobility relative to their normal or anticipated mobility. They
recommend considering pharmacological VTE prophylaxis for a
minimum of 7 days for patients who are undergoing open vascular
surgery or major endovascular procedures, including endovascular
aneurysm repair, and whose risk of VTE outweighs their risk of
bleeding. Further, they recommend considering mechanical
prophylaxis on admission for people who are undergoing open
vascular surgery or major endovascular procedures, including
endovascular aneurysm repair, if pharmacological prophylaxis is
contraindicated. SIGN published a relevant updated guideline
in 2014.400 The guideline notes that cardiac surgery patients
often receive anticoagulants and antiplatelet agents for reasons
independent of VTE and that this may impact their VTE risk.
Despite this, these guidelines recommend that patients undergoing
coronary artery bypass grafting surgery should be offered mechanical
thromboprophylaxis where feasible and that patients undergoing
coronary artery bypass grafting surgery who are not at high risk for
bleeding can also be offered pharmacological thromboprophylaxis.
The most relevant guideline on the perioperative management of
trauma patients is that by the ACCP in 2012.398 For major trauma,
including traumatic brain injury, acute spinal injury, and traumatic
spine injury, VTE prophylaxis is suggested (over no prophylaxis) with
LMWH, low-dose UFH, or mechanical prophylaxis, preferably with
intermittent pneumatic compression. For patients at high risk for
VTE, addition of mechanical prophylaxis to pharmacological pro-
phylaxis is suggested when not contraindicated by lower extremity
injury. It further suggests against placement of an IVC filter for primary
VTE prevention, as well as against periodic surveillance with venous
compression ultrasound.
A guidance document from the American College of Gynecology dates
back to 2007415; as a result, the 2012 ACCP guidelines provide the
timeliest guidance for gynecological surgery. One set of recommenda-
tions is made across gastrointestinal, urological, gynecological, bariatric,
vascular, plastic, and reconstructive surgery (see above).
Revision or adaptation of the guidelines
Plans for updating these guidelines
After publication of these guidelines, ASH will maintain them through
surveillance for new evidence, ongoing review by experts, and regular
revisions.
Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circum-
stances. These adaptations should be based on the associated EtD
framework.416 The Agency for Healthcare Research and Quality in
the United States provides a guide for implementing effective
quality improvement in this patient population.417
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